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ABSTRACT 
 
Background 
 
The mechanism by which allergies trigger asthma occurs through the interaction of antigen, IgE 
and the FcR1 receptor on mast cells resulting in the release of mediators that exert their effects 
on various surrounding tissues causing bronchoconstriction, plasma exudation and mucus 
hypersecretion.  The response is usually maximal within 30 minutes and resolves spontaneously 
within two hours.  At least half of the individuals who exhibit this so called “early response” also 
manifest a “late response” which is a subsequent episode of bronchoconstriction that is usually 
maximal around six hours following exposure and involves airway inflammation. 
 
Montelukast has proven efficacious in the management of asthma and desloratadine is effective 
in the treatment of allergic rhinitis and chronic idiopathic urticaria.  Since the early response 
involves the actions of multiple mediators, including histamine and the leukotrienes, the question 
of whether concurrent mediator blockade would be superior to either agent alone was raised.   
Additionally, the recent evidence supporting anti-inflammatory activity for these agents 
suggested potential efficacy against the late airway response.  
 
Methods 
 
Two double-blind, randomized, placebo-controlled, 4-way crossover allergen inhalation 
challenge investigations were conducted in twenty (10 per investigation) mild atopic asthmatics.  
The early response investigation involved the administration of either 5 mg desloratadine, 10 mg 
montelukast, the combination , or placebo (Vitamin B1) at 26 hours and 2 hours prior to allergen 
inhalation.  The late response investigation involved single dose administration of each agent, 
alone or in combination, 2 hours prior to allergen inhalation.  Measurements of changes in 
airway responsiveness and inflammation were also conducted. 
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Results 
 
The early response was significantly inhibited by montelukast and the combination.  
Desloratadine did not differ from placebo.  The late response was significantly decreased by 
desloratadine and montelukast and completely blocked with the combination.  Desloratadine 
decreased sputum eosinophils at 7 hours, montelukast at 24 hours, and the combination at both 
time points.   Airway responsiveness to methacholine trended lower with montelukast and the 
combination.  Montelukast was the only treatment to significantly decrease exhaled nitric oxide 
levels.  
 
Conclusion 
 
The combination of desloratadine and montelukast provides inhibition that is superior to both 
monotherapies on the early and the late airway responses to inhaled allergen in people with mild 
atopic asthma. 
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1.0  INTRODUCTION 
 
1.1 ASTHMA 
 
        1.1.1 Definition 
 
   A strict definition for asthma has been difficult to establish due to the 
heterogeneity of the disorder and the lack of a complete understanding of the events leading to 
the changes in airway physiology (i.e., hyperresponsiveness), pathology (i.e., inflammation) and 
structure (i.e., tissue remodeling).  The Global Initiative for Asthma (GINA), a partnership 
between the World Health Organization (WHO) and the United States National Heart Lung and 
Blood Institute (NHLBI, Bethesda Maryland, USA) provides the following “operational 
description” [GINA 2008] which remains controversial with noted limitations [Hargreave and 
Nair, 2009]: 
 
   “Asthma is a chronic inflammatory disorder of the airways in which many 
cells and cellular elements play a role.  The chronic inflammation is associated with airway 
hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing, particularly at night or in the early morning.  These episodes are 
usually associated with widespread, but variable, airflow obstruction within the lung that is often 
reversible either spontaneously or with treatment.” 
 
  1.1.2 Epidemiology 
 
   The prevalence of asthma continues to increase worldwide.   In 2005, the 
WHO reported an estimated 300 million individuals are affected by asthma and this is expected 
to increase by approximately 34% by 2025.  The WHO also reported 255,000 deaths due to 
asthma in 2005 and expects a 10% increase in mortality over the next 10 years.  Disease 
morbidity poses a huge burden to society both in terms of health care costs including emergency 
room visits, physician visits and drug costs, as well as school absenteeism and lost work days; 
this amounts to 6 billion dollars annually in the United States alone. 
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 Various risk factors have been identified and likely contribute to the asthma phenotype.  
Host factors such as genetic predispositions to atopy and airway hyperresponsiveness, as well as 
gender and obesity influence disease development. Environmental factors include agents to 
which individuals have a sensitivity (e.g., seasonal pollens and animal dander), tobacco smoke 
and air pollution which influence disease manifestation. 
   
  1.1.3 Atopic Asthma 
 
   Atopic asthma (a.k.a. allergic asthma or extrinsic asthma) describes a 
subpopulation of individuals that experience a worsening of their asthma upon exposure to 
allergens to which they are sensitized.  Atopic asthma is believed to account for more than 50% 
of adult asthma sufferers [WHO, 2003].  Common triggering antigens include seasonal pollens 
(e.g., grass, trees and weeds), house dust mite and domestic animals (e.g., cat and horse) and 
multiple sensitivities are usually present.  Atopy and asthma are not absolute co-morbidities; all 
individuals with asthma do not have allergies and all individuals with allergies do not have 
asthma.   
 
1.2 AIRWAY RESPONSES IN ATOPIC ASTHMA 
 
  1.2.1 Early and late asthmatic responses (Figure 1.1) 
 
   In the research setting, a standardized allergen challenge model has been 
developed to induce airway responses following allergen exposure allowing for the investigation 
of disease mechanism(s) and therapeutic efficacy [Boulet et al., 2007; Hendeles and Harman, 
1997].  Almost immediately following aerosolized (i.e., inhaled) administration of an allergen to 
which an individual is sensitized, the acute or early asthmatic response (EAR) develops.  The 
response is quantified by measuring changes in airflow and a positive result has been arbitrarily 
defined as a ≥ 20% (or 15%) decrease in the amount of air forcefully exhaled during the first 
second of expiration following a full inspiration (forced expiratory volume in one second,  
FEV1).   This reversible episode of airflow obstruction, which is usually maximal at 10 to 30 
 3
minutes post exposure, resolves within 3 hours of exposure, either spontaneously or with 
treatment.  Many individuals (50 to 75%) who develop an EAR will also develop a subsequent 
episode of 
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Figure 1.1:   Changes in FEV1 during the early and the late asthmatic responses. 
Grass inhalation results in a decrease in the FEV1 of approximately 30%.  The 
induced airflow obstruction is allowed to recover without treatment and returns to near baseline 
within three hours of allergen inhalation.  A subsequent decrease in FEV1 develops over the next 
4 hours in the absence of re-exposure to allergen. Saline challenge data is represented by open 
circles. Grass challenge data is represented by closed circles.  EAR, early asthmatic response. 
LAR, late asthmatic response. FEV1, volume of air forcefully exhaled during the first second of 
exhalation. 
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reversible airflow obstruction termed the late asthmatic response (LAR) arbitrarily defined as a 
decrease in FEV1 of ≥ 15%.  This delayed response develops over the 4 to 5 hours following 
resolution of the EAR, is usually maximal at 6 to 7 hours post inhalation, and is associated with 
inflammation, notably eosinophil recruitment, increased levels of exhaled nitric oxide, and 
increased airway hyperresponsiveness to direct acting stimuli (e.g., methacholine). 
 
1.2.2 Early asthmatic response - mechanism of action (Figure 1.2) 
 
   The EAR is an immunological Type I hypersensitivity reaction triggered 
by the interaction of allergen with allergen specific immunoglobulin E (IgE) which binds with 
high affinity to FcRI receptors on mast cells leading to mast cell degranulation and the release 
of various newly synthesized lipid derived mediators (e.g., cysteinyl leukotrienes) as well as 
preformed mediators (e.g., histamine) the physiological actions of which include 
bronchoconstriction, vasodilation, increased vascular permeability and mucus hypersecretion. 
IgE mediated mast cell activation also leads to the release of a variety of other mediators that 
function in immune regulation and inflammation, some of which are preformed (e.g., tumor 
necrosis factor alpha, TNF-) and some of which are produced within hours of activation (e.g., 
numerous interleukins, monocyte chemoattractant protein - 1 (MCP-1), macrophage inhibitory 
protein – 1 (MIP-1).  Activated mast cells are also a source of various cytokines, chemokines 
and growth factors which likely contribute to the development of the LAR and airway 
inflammation.  
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Figure 1.2:  Schematic of cellular events surrounding the early allergic/asthmatic response. 
Inhaled allergen will stimulate the release of preformed mediators and lipid derived mediators by 
crosslinking allergen specific IgE molecules bound to the high affinity IgE receptor (FcRI) on 
mast cells.  Mediators include histamine and the cysteinyl leukotrienes (cys-LT’s) the actions of 
which include bronchoconstriction, vasodilation, increased vascular permeability and mucus 
hypersecretion.  Mast cell activation also results in the synthesis and release of other mediators 
(cytokines, chemokines and growth factors) that function in leukocyte recruitment and likely 
contribute to the late allergic/asthmatic response. Modified from Galli, et al., [2008].
Histamine 
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1.2.3 Late asthmatic response - mechanism of action (Figure 1.3) 
 
   The mechanism of action of the late asthmatic response is not well 
defined.  Assuredly the response is a concerted action of numerous cells and mediators, some of 
which likely contribute to the recurrent airway narrowing including the cysteinyl leukotrienes 
and histamine, some of which propagate the inflammation (e.g., interleukins 4 and 13; IL-4, IL-
13) and some of which lead to chronic remodeling (e.g., matrix metalloproteinases, MMP’s, and 
major basic protein, MBP).  Our current understanding is that the LAR is driven by a T helper 
type 2 (Th2) cell inflammatory response predominantly orchestrated by the effects of Th2 
cytokines (i.e., IL-4, IL-5 and IL-13) including the recruitment and maturation of eosinophils as 
well as B cell immunoglobulin isotype switching and the production of IgE.  Recent reports 
however have dissociated the eosinophil from such a controlling role and we are looking to 
better understand the regulatory influence of other cells (e.g., basophils and dendritic cells) and 
other mediators (e.g., histamine, cysteinyl leukotrienes) on the development of the LAR.  
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Figure 1.3: Cells and mediators involved in the late allergic/asthmatic response.   
  Various cells and mediators likely contribute to the LAR.  Lymphocytes (notably 
Th2 lymphocytes), leukocytes (predominantly eosinophils) and the interleukins 4, 5 and 13 (IL-4, 
IL-5 and IL-13) are strongly implicated in the development of the LAR. CysLT’s, cysteinyl 
leukotrienes, GMCSF, granulocyte macrophage colony stimulating factor; RANTES, regulated 
upon activation, normal T cell expressed and secreted; PDGF, platelet derived growth factor; 
TGF, transforming growth factor beta;  TNF, tumour necrosis factor alpha; INF, interferon 
gamma; MCP-1, monocytes chemoattractant protein – 1. Modified from Chung and Adcock 
[2001].
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  1.2.4 Sequelae of the late asthmatic response 
   
   In addition to the reversible airflow obstruction that occurs in individuals 
that have an EAR with subsequent LAR, or dual asthmatic response (DAR), we also observe 
inflammation, changes in airway responsiveness to direct stimuli (e.g., methacholine, histamine) 
and increases in the level of exhaled nitric oxide.  Th2 driven leukocyte recruitment, eosinophils 
in particular, has been repeatedly documented by various methods including bronchoalveolar 
lavage (BAL), biopsy and sputum analysis [Beasley et al., 1989; Aalbers et al., 1993;  Pin et al., 
1992; Fahy et al., 1994].  Cysteinyl leukotrienes have also been shown to increase in sputum 
following allergen challenge [MacFarlane, et al., 2000]. The method of sputum induction and 
analysis is now a common procedure included in many allergen inhalation challenge protocols 
and provides valuable information about cellular events without the invasiveness of lavage or 
biopsy. 
  
   In addition to, or perhaps as a consequence of, inflammation, the airway 
also becomes hyperresponsive to direct stimuli (e.g., methacholine, histamine) following allergen 
exposure.  Allergen induced increases in airway hyperresponsiveness have been documented as 
early as 3 hours post exposure [Durham et al, 1988] and may remain for at least 7 days in some 
individuals [Cockcroft and Murdock, 1987]. The mechanisms leading to the increase in airway 
hyperresponsiveness are poorly understood and likely multifactorial [Cockcroft and Davis, 
2006]. 
 
   Levels of exhaled nitric oxide (FeNO) have also been shown to increase 
following allergen exposure [Kharitonov et al, 1995].  Measurement of FeNO is another non-
invasive and relatively simple procedure for assessing airway inflammation, eosinophilic 
inflammation in particular. Limitations of this technique are related to cost, both initially and for 
general preventative maintenance and the uncertainty surrounding the sensitivity and specificity 
of the test.  Nonetheless, the measurement of FeNO is being incorporated into many clinical 
research study designs to assess airway inflammation pre and post allergen exposure with and 
without treatment.  
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  1.2.5 Summary of airway responses in asthma 
 
   Allergen exposure in individuals with atopic asthma results in the 
development of an EAR and, in many, the subsequent development of an LAR.  In those who 
exhibit a DAR there is associated recruitment of inflammatory cells, changes in airway 
responsiveness to direct stimuli and an increase in FeNO, all of which can be induced and 
assessed under controlled conditions in a research setting which is an attractive model for 
studying the effects of novel therapeutic interventions. 
 
1.3 PHARMACOLOGY OF ASTHMA 
  
  1.3.1 General 
  
   Current guidelines recommend a hierarchy of therapeutic options, the 
choice of which depends upon the current level of asthma control.  The concept of control has 
largely replaced that of severity since an individual who is well controlled with proper treatment 
may indeed have severe disease.  Similarly, an individual receiving suboptimal treatment (i.e., 
poorly controlled) may have apparent severe disease; however, an individual who is extremely 
tolerant of airway obstruction may seem well controlled.  It should be appreciated therefore that 
treatment is not necessarily static, and that periodic re-assessment with both subjective and 
objective (i.e spirometry) data is required to avoid suboptimal or unnecessary therapeutic 
intervention.  In addition, the heterogeneity and various phenotypes of asthma (e.g., aspirin 
sensitive, atopic, chronic persistent, seasonal, etc.) make treatment choices and routine re-
evaluations rather important.  The role of the patient with respect to disease awareness and 
therapeutic compliance cannot be overstated when assessing the level of asthma control and 
treatment efficacy.   
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1.3.2 Available treatments 
  
   Most available asthma treatments fall into two broad categories defined as 
controller medications and rescue medications.  Rescue medications provide quick relief of 
bronchoconstriction and include the receptor agonists salbutamol and terbutaline.  Controller 
medications target airway inflammation and include the “gold standard” inhaled 
glucocorticosteroids (e.g., budesonide and fluticasone), as well as mast cell stabilizers (e.g., 
cromones), leukotriene receptor antagonists (e.g., montelukast and zafirlukast), 5-lipoxygenase 
enzyme inhibitors (e.g., zileuton), phosphodiesterase inhibitors (e.g., theophylline) and anti-IgE 
(omalizumab).  More recently, the combination of an inhaled glucocorticosteroid with a long 
acting  receptor agonist in a single inhaler has become available (e.g., budesonide/formoterol 
and fluticasone/salmeterol).  Occasionally systemic steroid (i.e., prednisone) and anti-viral 
therapies may be indicated and annual vaccinations can be beneficial in certain individuals. 
   
   In spite of the many currently available treatments which are very 
effective at controlling and managing asthma in the majority of patients, none have been shown 
to be disease modifying or curative.  Furthermore, excessive use of some treatments, 
conventional 2 agonists for example, may result in an increase in responsiveness to allergen, 
and in tolerance to its bronchoprotective effects against direct stimuli [Cockcroft et al, 1993] as 
well as contribute to inflammation [Gordon et al, 2003]. Additionally, high dose or long term 
chronic dosing with inhaled corticosteroid can increase the risk of undesirable side effects, 
especially in the young and old [Dahl 2006].  There is therefore an ongoing need to develop 
alternative therapies which would ideally alter the development, course or manifestation of the 
disorder and/or decrease the potential untoward effects of the currently available controller and 
rescue medications.  
 
  1.3.3 Investigational therapies 
 
   Over the last twenty years anti-asthma treatments have undergone few 
changes.  For the most part, new treatments are the result of modifications of existing therapies 
or the development of new delivery devices.  For example, bronchodilators are now “long 
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acting” extending the duration of action to twelve hours (e.g., salmeterol and formoterol) instead 
of the four to six hour duration of the short acting bronchodilators (e.g., salbutamol).  Many of 
the available therapies are delivered via dry powder inhalers as well as the conventional aerosol 
delivery systems.  These patterns of change are continuing as evidenced by recent investigations 
of “ultra” long acting beta agonists capable of bronchodilating the airway for up to 24 hours 
[Beeh et al, 2007; Brookman et al, 2007] and bronchoprotecting the airway for up to 32 hours 
[O’Byrne et al, 2009] that, in some cases, are being delivered by inhaler devices designed to 
provide superior deposition [Dalby et al, 2004; Watts et al, 2008].   With the exception of 
ciclesonide, a prodrug design corticosteroid that is converted to its active component in the lung, 
inhaled anti-inflammatory treatments have seen little progress.  The most significant therapeutic 
development in the last 10 years was the introduction of a new class of drug, the leukotriene 
modifiers which include the leukotriene receptor antagonists (e.g., montelukast and zafirlukast) 
as well as the 5-lipoxygenase enzyme inhibitor, zileuton.  These agents offer no immediate relief 
of bronchoconstriction and as such are recognized as controller therapy.  Leukotriene receptor 
antagonists have proven particularly beneficial as add on therapies to currently available 
bronchodilator or anti-inflammatory treatments when control is suboptimal.  Leukotriene 
receptor antagonists are also useful in controlling exercise induced bronchoconstriction and have 
shown benefit for those with aspirin induced asthma [Blake, 1999; Currie and McLaughlin, 
2006]. 
 
   Recent research has deviated from the traditional therapeutic strategies by 
targeting specific mediators, signaling molecules and proteins that are released, activated or up-
regulated following allergen exposure [O’Byrne, 2006].  In addition to the release of cysteinyl 
leukotrienes and histamine, mast cell degranulation results in the release of proteoglycans (e.g., 
heparin), proteases (e.g., tryptase), non-cysteinyl leukotriene eicosanoids (e.g., PGD2 and LTB4) 
and numerous cytokines (e.g., IL-3, IL-5).  The recent assessment of a heparin derivative devoid 
of anti-coagulant activity failed to produce statistically significant reductions of the EAR, LAR 
or late sequelae in a proof of concept study in humans. This was perhaps disappointing given the 
positive pre-clinical data in sheep [Ahmed et al, 2000] but a trend toward a reduction of the 
response was evident following this single dose investigation suggesting multiple and/or higher 
doses may be necessary for efficacy [Duong et al, 2008].  An antisense oligonucleotide targeting 
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CCR3 and the common beta chain of IL-3, IL-5 and GM-CSF were found to protect against the 
EAR, decrease sputum eosinophilia, and suppress the allergen induced increase in CCR3 and 
beta chain mRNA [Gauvreau et al, 2008].   An interesting finding from this investigation 
however was the lack of efficacy on the LAR perhaps providing clinical evidence that eosinophil 
recruitment may not be a major player in the LAR as initially believed.  It is possible however, 
that the negative results may be related to the dose, dosing sequence, dosing mechanism or 
biological effect.  Investigations of inhaled anti-sense oligonucleotide therapies for the treatment 
of asthma are in their infancy.  Other targets include adhesion molecules that play a role in 
inflammatory cell recruitment and therefore, at least theoretically, blocking these proteins would 
suppress the LAR.  Efalizumab, an anti-CD11a, IgG1 monoclonal antibody targeting lymphocyte 
function associated antigen-1 (LFA-1) demonstrated a significant decrease in inflammatory cell 
recruitment but also failed to inhibit the EAR or the LAR [Gauvreau et al, 2003].  LFA-1 is 
involved in cellular adhesion and leukocyte recruitment and it was not surprising that a 
significant decrease in inflammatory cells was achieved.  However, the results provide additional 
clinical evidence that inhibiting inflammatory cell recruitment does not correlate with a reduction 
in the LAR. Investigations of a nebulized soluble IL-4 receptor (sIL-4R) produced positive data 
in moderate and/or severe asthma preventing the loss of asthma control during steroid 
withdrawal [Borish et al, 1999; Borish et al, 2001] and promising preclinical data has shown an 
IL-4 vaccine, administered prior to ovalbumin sensitization, to be very effective in a murine 
model of allergic asthma decreasing inflammatory cell influx, preventing the formation of 
ovalbumin specific IgE and inhibiting the increase in airway responsiveness to methacholine five 
weeks after vaccination [Ma et al, 2007].  A recombinant human interleukin-4 variant, which 
competitively inhibits the binding of both IL-4 and IL-13 with IL-4R significantly decreased 
the LAR and baseline FeNO but had no effect on the allergen induced increase in AHR to 
methacholine or adenosine monophosphate  [Wenzel et al, 2007].  Unfortunately, the effect on 
inflammatory cell influx was not evaluable.   These effects were seen after four weeks of 
treatment with either 25 mg/day administered subcutaneously or 60 mg/bid via nebulization.  
The authors reported no change in the average percent fall in FEV1 during the EAR (0 to 2 h post 
challenge) but did not report on the AUC or maximal decrease in FEV1.  Mepolizumab, a 
humanized anti-IL-5 molecule has been shown to decrease blood and sputum eosinophils 
following allergen inhalation but failed to inhibit the LAR [Leckie et al, 2000].   Similar results 
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were obtained with a recombinant human IL-12 molecule [Bryan et al, 2000].  In severe 
corticosteroid dependent and refractory asthma, etanercept, an anti-TNF fusion protein, 
improved asthma control, lung function and airway responsiveness to direct stimuli [Howarth et 
al, 2005; Berry et al, 2006]. Other monoclonal antibodies targeting IL-9 and IL-13 are in 
development and undergoing early clinical testing.  
 
   The information gained from these investigations challenges our current 
understanding of the role of inflammation in asthma following allergen exposure in individuals 
with mild atopic asthma.  Specifically, the lack of efficacy on the LAR despite an inhibitory 
effect on inflammatory cell influx suggests that inflammation may not be as causally related, at 
least with respect to the LAR, as we currently surmise.   In addition to the ever difficult issue of 
moving from animal to human models, we must consider how the dose, delivery, subject 
characteristics/disease heterogeneity and method of assessment of these agents undergoing early 
development might be influencing the outcome before drawing any conclusions.    
 
   The reality of bringing these types of drugs to market for routine asthma 
management seems somewhat unlikely for many reasons including cost and mode of delivery.  
However, those individuals whose asthma is uncontrolled by currently available treatments may 
potentially benefit from these types of biological agents.   
 
1.4 PHARMACOLOGY OF THE EAR AND LAR (Table 1.1) 
  
1.4.1 Beta2 agonists 
 
   Beta2 agonists (e.g., salbutamol) are bronchodilator agents that relax 
airway smooth muscle by increasing levels of cAMP.  These agents are also referred to as rescue 
agents or relievers.  In the research setting, pre-administration of an inhaled short acting 2 
agonist results in an increase in the amount of allergen administered to cause a 20% fall in FEV1 
by nearly 4 doubling doses or 16 fold [Cockcroft et al., 1993].  These agents are therefore very 
effective in blocking the early response and this effect is often described as “functional 
antagonism”.  For this reason, short acting bronchodilators are withheld for their duration of 
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action prior to EAR investigations and similar rationale pertains to long acting 2 agonists (e.g., 
salmeterol).  The longer duration of action results in the inhibition of both the early and late 
responses as well as the associated increase in airway hyperresponsiveness.  The main 
mechanism of the inhibition is believed to be the result of functional antagonism at the level of 
the airway smooth muscle. However, terbutaline has been shown to shift the dose response curve 
to adenosine 5’-monophosphate (AMP) nearly five doubling dilutions implicating mast cell 
stabilization as an additional mechanism [O’Connor et al., 1994]. Clinically, these agents serve 
to reverse acute bronchoconstriction, induced by allergen exposure or other triggers (e.g., 
exercise).  Similarly, the LAR inhibition seen with long acting 2 agonist use is likely an 
apparent inhibition resulting from a masking of the response by functional antagonism rather 
than a prevention of the response via anti-inflammatory mechanisms.   
 
  1.4.2 Inhaled glucocorticosteroids 
 
   Inhaled glucocorticosteroids (e.g., beclomethasone, fluticasone) also block 
airway responses to inhaled allergen.  Chronic, stable dosing will partially block the early 
response [Cockcroft et al., 1995] and a single dose administered before [Pepys et al., 1974; 
Cockcroft and Murdock, 1987] or after [Cockcroft et al., 1993] the EAR will prevent the LAR.  
Interestingly, the inhibitory effects on the EAR and LAR, afforded by one week of stable dosing 
are diminished within 12 hours of drug withdrawal [Subbarao et al., 2005]. In isolated early 
response investigations, inhaled steroids are often administered after the challenge as a safety 
measure to prevent the LAR from occurring.  The majority of protocols require inhaled (or 
systemic) steroids be withheld for at least four weeks prior to enrollment to avoid confounding 
the anti-inflammatory efficacy of the agent under investigation.  The effects of corticosteroids 
are potentially numerous and result from the trans-activation (i.e., induction) of anti-
inflammatory genes and related proteins or trans-repression (i.e., inhibition) of inflammatory 
genes and related proteins.  The result for example, may be an increase in lipocortins which 
inhibit the activity of phospholipase A2 and therefore the production of arachidonic acid 
metabolites or conversely a decrease in the synthesis of pro-inflammatory mediators such as 
GM-CSF, IL-4, IL-5 and IL-13. [van der Velden, 1998]. 
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   1.4.3 Cromones (Mast cell stabilizers) 
 
    Cromones, including sodium cromoglycate and nedocromil 
sodium, are nonspecific chloride channel blockers that alter the function of many cells including 
mast cells and eosinophils.  As such, these agents effectively suppress the early and late airway 
responses as well as the increase in allergen-induced airway hyperresponsiveness [Hendeles et 
al., 1995; Cockcroft and Murdock, 1987].  These agents, although rarely used in Canada, would 
need to be withheld for their duration of action prior to allergen challenge investigations. 
 
1.4.4 Monoclonal antibodies 
 
    To date, only one biologic agent has been approved for use in the 
treatment of asthma.  Omalizumab, a humanized anti-IgE molecule, binds free IgE and prevents 
the interaction of IgE with its high affinity FcR1 receptor on basophils and mast cells.  By 
blocking the IgE mediated cross-linking of receptors, degranulation and mediator release is 
prevented.  Anti-IgE significantly inhibits the early and the late airway responses as well as the 
late sequelae [Boulet et al., 1997; Fahy et al., 1997].  Individuals currently treated with anti-IgE 
therapy would be excluded from allergen challenge investigations for at least two reasons.  First, 
and most important, these individuals would not be well controlled without therapy and second, 
the treatment would confound the results. 
 
   1.4.5 Leukotriene modifiers 
 
    These agents include the leukotriene receptor antagonists 
montelukast, pranlukast and zafirlukast as well as the enzyme (synthesis) inhibitors (e.g., 
zileuton, Bay x1005 and MK-0591).  Montelukast [Diamant et al., 1999; Leigh et al., 2002; 
Palmqvist et al., 2005], pranlukast [Hamilton et al., 1998] and zafirlukast [Dahlen et al., 1991] 
have all been shown to partially block both the early and late allergen induced airway responses.  
Enzyme inhibitors have not evolved as clinically useful treatments in protecting against the EAR 
and LAR.   The leukotriene receptor antagonists are competitive inhibitors of CysLT1 receptors 
and the enzyme inhibitors block the formation of LTA4 the precursor of LTB4 and the cysteinyl 
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leukotrienes LTC4, LTD4 and LTE4.   These agents must also be withheld prior to allergen 
challenge investigations. 
 
1.4.6 Histamine H1 blockers 
 
    Antihistamines, more specifically histamine H1 receptor 
antagonists have been extensively investigated over the years.  These agents produce little, if 
any, protection against the EAR and the LAR.  First generation H1 receptor antagonists displayed 
some bronchodilatory properties but produced various side effects due to receptor non-specificity 
(e.g., antimuscarinic).  These agents also readily crossed the blood brain barrier which, in 
addition to their non-histaminergic effects, discouraged further interest in these drugs as potential 
therapies in the management of asthma [Holgate and Finnerty, 1989; Simons, 2004].  This was 
perhaps disappointing in view of the extensive evidence to support a role for histamine as a 
causative agent of bronchoconstriction [Cockcroft et al., 1977, Boushey et al., 1980] and the 
similar mechanism of action (i.e., mast cell mediator release) shared by other allergic conditions, 
such as rhinitis, conjunctivitis and urticaria for which these agents are the drug of choice.    
 
    Second generation H1 antihistamines (e.g., loratadine) do not cause 
the same untoward effects as first generation antihistamines, and investigations into their 
potential use in asthma are once again of great interest.  Partial inhibition of both early and late 
airway responses to allergen have been documented with second generation antihistamines 
[Rafferty et al., 1989; Twentyman et al., 1993;  Bentley et al., 1996].
 Table 1.1 Effects of various drugs on allergen induced airway responses 
DRUG TYPE EFFECT ON EAR 
EFFECT 
ON LAR 
EFFECT 
ON LATE SEQUELAE 
SHORT ACTING 2 AGONISTS  (salbutamol) INHIBIT NO CHANGE NO CHANGE 
LONG ACTING 2 AGONISTS (salmeterol) INHIBIT INHIBIT NO CHANGE 
REGULAR USE OF SHORT ACTING 2 AGONIST AUGMENT AUGMENT AUGMENT 
MUSCARINIC ANTAGONIST (ipratropium bromide) MINOR INHIBITION MINOR INHIBITION NO CHANGE 
GLUCOCORTICOSTEROID (beclomethasone dipropionate) 
SINGLE DOSE AFTER EAR N/A INHIBIT 
MODERATE ↓AHR 
EOS UNKNOWN 
GLUCOCORTICOSTEROID - SINGLE DOSE PRE CHALLENGE 
NO CHANGE INHIBIT MODERATE  INHIBITION 
GLUCOCORTICOSTEROID - CHRONIC STABLE DOSE MODERATE  INHIBITION INHIBIT INHIBIT 
THEOPHYLLINE MINOR INHIBITION MINOR INHIBITION NO CHANGE AHR EOS UNKNOWN 
CROMONES (sodium cromoglycate) MODERATE INHIBITION 
MODERATE 
INHIBITION 
MODERATE ↓AHR 
EOS UNKNOWN 
ANTI-IGE (omalizumab) INHIBIT INHIBIT INHIBIT 
LTRA (zafirlukast) MODERATE INHIBITION 
MODERATE 
INHIBITION 
MODERATE INHIBITION 
(BOTH) 
ANTI-HISTAMINE (loratadine) PARTIAL  INHIBITION 
VARIABLE 
 INHIBITION UNKNOWN 
SINGLE DOSE ANTI-HISTAMINE + LTRA 
(desloratadine + montelukast) INHIBIT INHIBIT 
TREND TO ↓  AHR 
↓ EOS 
18
19 
1.5 INTRODUCTION SUMMARY 
 
  Asthma prevalence is increasing and atopy, the prevalence of which is also 
increasing [Pawankar et al., 2008], is a contributing factor.  The response to allergen exposure in 
sensitized individuals includes the relatively rapid development of bronchoconstriction, the EAR, 
and in some, a subsequent episode of bronchoconstriction, the LAR and its associated sequelae 
of inflammation, increased airway hyperresponsiveness to direct stimuli and increased levels of 
exhaled nitric oxide.  Various therapeutic options are available to relieve bronchoconstriction 
and control inflammation.  Clinical research is focusing on biologics that target various pro-
inflammatory molecules or their receptors.  These entities, if developed and approved, may 
benefit a small percentage of individuals with difficult to treat or refractory disease.  The 
leukotriene modifiers are the most recently approved treatment for asthma, and second 
generation antihistamines, with improved pharmacodynamic and safety profiles, have renewed 
our interest in the role of histamine and antihistamines in asthma pathogenesis and treatment. 
  
1.6 STUDY RATIONALE 
 
  The EAR is a Type I hypersensitivity reaction involving the release of mast cell 
mediators that include the leukotrienes and histamine.  The leukotriene antagonists provide only 
partial inhibition of the EAR, and minor, variable effects have been shown with first generation 
antihistamines.  Second generation antihistamines are more selective for the histamine H1 
receptor and have fewer side effects than their predecessors which warrant re-investigation of 
their efficacy in asthma.  Inhibition of the EAR should be possible by blocking the effects of 
mast cell mediators (e.g., histamine and the cysteinyl leukotrienes), and concurrent blockade 
should be superior to single mediator blockade. We hypothesized that the combination of a 
leukotriene receptor antagonist (montelukast) with a newer second generation antihistamine 
(desloratadine) would provide better protection against the EAR by concurrent blockade of the 
direct effects of histamine and the leukotrienes on their respective airway smooth muscle cell 
receptors.  If this were true, the combination of desloratadine and montelukast may also be 
effective in blocking the LAR in view of the recent evidence of the anti-inflammatory and 
immunoregulatory activity of these two therapeutic entities. 
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2.0 LITERATURE REVIEW 
  
  2.1 Histamine 
   
   2.1.1 Introduction 
   
    Histamine is a biogenic amine first discovered by Sir Henry Dale 
in the early 1900’s [Holgate and Dahlen, 1997].  The physiologic role of histamine extends over 
various systems including the central nervous system where it influences wakefulness, motor 
coordination, memory and learning; the gastrointestinal system where it plays a major role in 
gastric acid secretion; and the respiratory system where its best known effect is smooth muscle 
contraction and bronchoconstriction.  Histamine also plays a role in immune responses and in the 
process of inflammation [Schneider et al, 2002; Akdis and Blaser, 2003; Jutel et al, 2006]. 
 
   2.1.2 Biosynthesis, Storage and Release 
   
    Histamine is synthesized from L-histidine by histamine 
decarboxylase and stored in mast cells and basophils.  Histamine is metabolized by N-
methyltransferase to N-methyl histamine which is subsequently broken down by monoamine 
oxidase to N-methyl imidazole acetic acid.  An alternative metabolic pathway forms imidazole 
acetic acid through diamine oxidase activity (Figure 2.1).  These metabolites, along with a small 
percentage of unchanged histamine are excreted in the urine and the levels excreted are 
sometimes used as a measure of histamine release.  There is also evidence that histamine is 
synthesized “on demand” by cells that have high histamine decarboxylase activity such as 
dendritic cells and T cells and this characteristic may be important in our understanding of the 
role of histamine in immune and inflammatory responses. 
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Figure 2.1 Histamine biosynthesis and metabolism. MAO, monoamine oxidase B 
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   2.1.3 Histamine receptors 
   
    Four histamine receptors have now been identified (H1 through H4) 
all of which are G protein coupled and have various tissue expression.  Histamine and histamine 
metabolites bind to the different receptors with varying affinities.  (Table 2.1)  The H1 receptor 
exists in two states, active and inactive, and expresses constitutive activity.  Agonists will signal 
activation whereas antagonists, or in this case, inverse agonists, stabilize the receptor in an 
inactive state.   
 
   The H1 receptor is coupled to Gq/11 and the binding of histamine 
results in the activation of  phospholipase C (PLC) and the inositol trisphosphate (IP3) 
diacylglycerol (DAG) intracellular signaling pathway.  IP3 mobilizes intracellular Ca2+ resulting 
in increased kinase activity (e.g., myosin light chain kinase) and protein phosphorylation; DAG 
stimulates PKC which also leads to protein phosphorylation (e.g., myosin light chain).  The 
overall effect of histamine H1 receptor activation via this pathway is a reduction in airway caliber 
and decreased air flow (i.e., bronchoconstriction) as a result of airway smooth muscle 
contraction.  Through this mechanism, the administration of exogenous histamine via inhalation 
was a useful diagnostic and research tool in respiratory disease before being largely replaced by 
methacholine, a muscarinic agonist that mimics acetylcholine (i.e., binds to M2 receptors on 
airway smooth muscle) and causes bronchoconstriction.  The H1 receptor is expressed on a 
variety of cells including endothelial, epithelial, leukocytes, lymphocytes, nerve, antigen 
presenting (e.g., dendritic cells) and smooth muscle.   
 
   The H2 receptor is coupled to the Gs protein and signals through 
the adenylyl cyclase (AC ) – cAMP – protein kinase A (PKA) second messenger system.  The H2 
receptor shares similar expression patterns with H1 and its major physiological role, to date, is 
the stimulation of proton release from parietal cells.  H2 antagonists are widely prescribed for the 
treatment of gastric ulcers (e.g., ranitidine, cimetidine). There is some evidence that H2 activation 
in the lung leads to smooth muscle relaxation but this is not a clinical use. 
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   Histaminergic neurons in the central nervous system express H3 
receptors which regulate histamine synthesis and release through an autoreceptor mechanism.  
This inhibitory function signals through the Gi/o cAMP pathway.   In addition to its 
autoregulatory function, H3 receptor activation may also regulate the levels of other 
neurotransmitters such as serotonin, dopamine and GABA.  There is considerable interest in the 
development of H3 agonists and antagonists for the treatment of CNS disorders including 
migraine, obesity, ADHD, Alzheimer’s and epilepsy but there are no currently available 
treatments. 
 
   The most recently described histamine receptor is the H4 receptor 
which is highly expressed on leukocytes and in bone marrow.  Ligand receptor interactions are 
coupled to the Gi/o  protein, adenylyl cyclase, cAMP pathway.  Since the cloning of the gene 
encoding the human H4 receptor in 2000, investigations into the role of the H4 receptor and 
possible therapeutic implications have received much attention.  Our current understanding 
suggests a major role for histamine acting via the H4 receptor in immunoregulation and 
inflammation which implicates agonists or antagonists of the H4 receptor as possible therapeutic 
intervention in immune and inflammatory disease.  Indeed, early clinical investigations are being 
conducted in atopic asthma. 
 
         
  Table 2.1: Histamine receptor properties 
RECEPTOR 
SUBTYPE EXPRESSION 
G 
PROTEIN 
PREDOMINANT 
SIGNALING 
PATHWAY 
PHYSIOLOGICAL
EFFECTS ANTAGONISTS pKa 
H1 
Smooth muscle 
Endothelial 
cells 
CNS 
Gq/11 
↑ PLC-IP3/DAG ↑ 
Ca2++ 
Bronchoconstriction 
Vascular leakage 
 
Chlorpheniramine 
 
(DESLORATADINE)
4.2 
H2 
GI tract 
Cardiac muscle 
Mast cells 
CNS 
Gs ↑ AC-cAMP-PKA Gastric acid secretion Ranitidine 4.3 
H3 CNS Gi/o ↓ AC-cAMP 
Autoregulation of 
presynaptic 
neurotransmitter 
release 
Thioperamide 
Clobenpropit 7.8 
H4 
Hematopoietic 
Cells Gi/o 
↓ cAMP 
↑ Ca2++ 
Immunoregulation 
Anti-inflammatory Thioperamide 8.4 
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2.1.4 Histamine H1 receptor antagonists 
   
    The effects of inhaled histamine are inhibited by the administration 
of selective H1 blockers.  This has been shown to be agent specific in that the extent of inhibition 
varies with the drug.  The greatest inhibition (> 3 doubling doses) is afforded by the second 
generation antihistamine cetirizine and the least by the first generation antihistamine 
chlorpheniramine [Wood-Baker and Holgate, 1993]. These differences are probably due to 
differences in receptor selectivity (i.e., additional anticholinergic, antiserotinergic and 
antiadrenergic activity).  As yet however, antihistamines have found limited clinical use in the 
treatment of atopic asthma despite the theoretical rationale based on the action of histamine in 
the acute response following allergen exposure.  The minimal, at best, inhibitory effect on 
allergen-induced airway responses following antihistamine administration supports the rationale 
that blocking more than one mediator may be required to inhibit a response that results from the 
action of many mediators.  Somewhat puzzling perhaps is that H1 blockers are the drug of choice 
in the treatment of allergic rhinitis and chronic idiopathic urticaria, conditions which share 
similar pathophysiology with atopic asthma but, unlike atopic asthma, respond relatively well to 
these agents.   Individuals who have concomitant hay fever and asthma have been shown to 
benefit from anti-histamine treatment.  Whether this is a mechanistic phenomenon occurring in 
the lung as well as the nasal passage or a physiologic reaction whereby treatment of a condition 
of the upper airway benefits that of the lower airway has not been elucidated but is being 
investigated [Hellings and Ceuppens, 2004; Jeffrey and Haahtela, 2006]. 
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2.2 Desloratadine 
 
  2.2.1 General Information 
 
   Desloratadine is the most potent active metabolite of the second 
generation antihistamine loratadine.   Desloratadine was approved by the United States Food and 
Drug Administration (FDA) in late 2001 for the treatment of allergic rhinitis, conjunctivitis and 
chronic idiopathic urticaria (CIU) in both children and adults.  Premarketing clinical trials and 
Phase IV clinical trial (i.e., postmarketing) data have established that the drug is safe and well 
tolerated.  Classical undesirable effects of first generation antihistamines (e.g., impaired motor 
function and altered wakefulness) have not been observed, there is no effect on cardiovascular 
function, and no concerns regarding drug-food or drug-drug interactions.  The recommended 
dose for adults is 5 mg once a day. 
 
  2.2.2 Mechanism of action and PK/PD properties 
  
   Desloratadine is a tricyclic selective histamine H1 receptor antagonist 
which binds with high affinity to the histamine H1 receptor (Figure 2.2).  Following oral 
administration plasma concentrations are maximal at about 3 hours and, on average, 85% of the 
drug is bound to plasma proteins.  The half life is approximately 27 hours.  Desloratadine 
undergoes hydroxylation and glucuronidation and its metabolites are excreted in both urine and 
feces. 
 
Figure 2.2: Chemical structure of desloratadine. 
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2.2.3 Effects of desloratadine in allergic rhinitis and chronic idiopathic 
urticaria 
 
   The beneficial effects of once daily dosing with desloratadine in allergic 
rhinitis  and chronic idiopathic urticaria (CIU) have been well documented [reviewed by 
Murdoch et al., 2003].  Significant improvements in total symptom scores, nasal discharge, 
sneezing and pruritis for example are consistent findings.   Decreases in asthma symptom scores 
and in rescue medication use have also been shown in allergic rhinitis with concomitant asthma, 
and improvements in FEV1 occur in individuals with resting obstruction (i.e., baseline FEV1 ≤ 
80% predicted).   Most studies have looked at dosing once a day for ≥ 4 weeks but improvements 
have been noted for some variables after a single dose and as early as 12 hours.  These effects are 
superior to those seen with other second generation antihistamines such as fexofenadine. 
 
  2.2.4 Effects of desloratadine on immune and inflammatory responses 
 
   Of significant interest are the emerging data on the potential anti-
inflammatory and immunomodulatory effects of anti-histamines, desloratadine in particular.  An 
ex vivo analysis of the effect of desloratadine on IgE mediated and non-IgE mediated LTC4, 
tryptase and ECP release in nasal polyp tissue from 22 subjects with chronic rhinosinusitis was 
recently reported [Kowalski et al., 2005].  The authors concluded that the H1 blocker 
significantly decreased the release of tryptase following Ca2+ ionophore and anti-IgE stimulation.  
The same effect was seen with respect to LTC4 release however inhibition of the IgE mediated 
release was only observed following the 10 g/mL stimulation and not the 1 or 100 g/mL 
stimulation.  Non IgE mediated stimulation of eosinophil cationic protein (ECP) release was 
reduced by almost 60 % following desloratadine pretreatment.  In another ex vivo investigation, 
Schroeder et al., [2001] looked at the effect of fifteen minutes of pretreatment with desloratadine 
on histamine, LTC4, IL-4 and IL-13 release from basophils activated by a variety of stimuli.  
They were able to show a dose dependent inhibition of IL-4 and IL-13 release that was superior 
to that of LTC4 and histamine release regardless of whether basophil stimulation occurred via 
IgE dependent or IgE independent mechanisms.  At the highest dose of desloratadine (10 M) 
IL-4 secretion was inhibited by approximately 80 % whereas that of histamine and LTC4 was 
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about 60 %.  The effect on IL-13 release was similar (i.e., approximately 80 % inhibition at 10 
M).  The authors also showed that the reduction in the amount of IL-4 released may be due to 
the inhibition of IL-4 mRNA.  This was also seen in COS-7 cells where desloratadine, and other 
H1 antagonists, inhibited both basal and histamine induced NFB activity suggesting negative 
regulation of gene transcription of pro-inflammatory mediators as a possible mechanism [Wu et 
al., 2004].   Another ex vivo investigation using FcR1 cells from peripheral blood, skin and lung 
tissue (i.e., mast cells and basophils) confirmed the inhibitory effect of desloratadine on 
histamine, tryptase, LTC4 and PGD2 release from these cells [Genovese et al, 1997].  A unique 
fluorescent methodology using the mast cell engulfing agent sulforhodamine-B (SFRM-B) 
suggests desloratadine may be exerting its effects through mast cell stabilization [Wang et al, 
2005].   Two additional investigations in Balb/c mice have implicated histamine as an important 
signal during the sensitization phase to allergen as well as at the time of subsequent exposure.  
Both studies showed that desloratadine decreased Th2 responses when administered at either time 
point as evidenced by suppression of IL-4, IL-5 or IL-13 [Bryce et al., 2003; Blumchen et al., 
2004].  
 
  A recent double blind parallel group investigation in a cohort with rhinitis and 
asthma compared the efficacy of eight days of 5 mg per day desloratadine with placebo on the 
response to nasal provocation in 26 grass pollen sensitive individuals.  Desloratadine was shown 
to improve baseline peak nasal inspiratory flow and decrease the number of circulating 
eosinophils following treatment but prior to nasal challenge [Reinartz et al., 2005].  This 
suggests a lack of protective efficacy to events occurring after exposure but a beneficial effect on 
underlying inflammation (i.e., an improvement in baseline nasal airflow obstruction).    
 
  These recent investigations provide evidence to suggest that desloratadine may be 
an effective therapeutic agent in the treatment of airway responses to inhaled allergen by 
inhibiting the release of bronchoconstricting (e.g., LTC4 and histamine) and pro-inflammatory 
(i.e., IL-4, IL-5 and IL13) mediators from cells that are known to contribute to the 
pathophysiology of atopic asthma and the airway response to allergen exposure (i.e.., mast cells 
and basophils). 
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2.3 Cysteinyl Leukotrienes 
 
  2.3.1 Introduction 
  
   In 1938, Charles Kellaway and William Siegmund Feldberg were the first 
to describe a substance that was produced following antigen challenge that, like histamine, 
caused smooth muscle contraction.  The response however was slower in onset and longer in 
duration.  They termed the substance “slow reacting substance; SRS”.  Shortly afterward, 
experiments by Walter Edwin Brocklehurst led to the terminology “slow reacting substance of 
anaphylaxis; SRS-A” and finally, in the early 1980’s, it was realized that SRS-A was actually 
LTC4, LTD4 and LTE4 – the cysteinyl leukotrienes [Holgate and Dahlen, 1997]. 
 
  2.3.2 Biosynthesis  (Figure 2.3) 
   
   The cysteinyl leukotrienes are products of arachidonic acid metabolism.  
Arachidonic acid is a component of membrane phospholipids of many cell types, including those 
that play a major role in atopic asthma (e.g., mast cells, eosinophils, basophils).  Enzymatic 
cleavage by phospholipase A2 releases arachidonic acid from the perinuclear membrane which 
serves as a substrate for 5 lipoxygenase in the formation of LTA4 and 5-
hydroperoxyeicosatetraenoic acid (5-HPETE).  LTA4 undergoes conjugation with glutathione by 
LTC4 synthase to form LTC4 which is actively transported out of the cell where further 
enzymatic action forms LTD4 and subsequently LTE4.  Native LTE4 and various degradation 
products can be found in the urine and have been used, for example, as a measure of IgE 
mediated mast cell degranulation. 
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Figure 2.3:  Biochemical Pathways of the Formation and Action of the Leukotrienes and Sites 
of Action of Leukotriene-Modifying Drugs.   
 
  Enzymes are shown in blue, products in yellow, essential cofactor in green, and 
drugs in red.  Although the synthesis of leukotrienes B and C probably takes place in close 
proximity to the nuclear membrane, for clarity they are shown throughout the cytosol. BLT 
denotes the B leukotriene receptor.  An individual cell may produce the cysteinyl leukotrienes, 
leukotriene B, or in rare cases both. Reproduced with permission from Drazen et al., [1999]. 
Copyright © 1999 Massachusetts Medical Society. All rights reserved. 
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  2.3.3 Leukotriene receptors 
  
   Two cysteinyl leukotriene receptors, (CysLT1 , CysLT2) have been 
identified and evidence supporting the existence of a third is emerging.  The cysteinyl 
leukotrienes bind to CysLT1 and CysLT2 with varying affinities.  LTD4 > LTC4 > LTE4 and 
LTC4 = LTD4 > LTE4 for CysLT1 and CysLT2 respectively.  Both receptors are differentially 
expressed on various cell types and tissues including bronchial smooth muscle, 
monocytes/macrophages, mast cells, eosinophils and basophils.   Their expression has been 
shown to be upregulated in the presence of various cytokines, including Th2 generated IL-4, IL-5 
and IL-13.   The CysLT receptors, like the histamine receptors are coupled to G proteins.  
CysLT1 is coupled to Gq/11 and Gi/o and CysLT2 to Gq/11.  Little is understood about 
subsequent signal transduction mechanisms. 
 
  2.3.4 Leukotriene modifiers 
   
   2.3.4.1     Enzyme inhibitors 
    
        While various enzyme inhibitors have been studied for efficacy 
in asthma, only one, zileuton, is currently available.  Zileuton inhibits 5-lipoxygenase and 
prevents the synthesis of leukotriene A4 from arachidonic acid.  In the absence of LTA4 
subsequent downstream products for which LTA4 is a substrate are also downregulated, namely 
LTB4 and the cysteinyl leukotrienes LTC4, LTD4 and LTE4.  There were two identifiable reports 
in the literature that looked at the effect of zileuton on the response to allergen challenge in 
atopic asthma.  The first looked at a single dose administered 3 hours prior to allergen challenge 
in nine male atopic asthmatics.  The investigators found that 800mg of zileuton failed to 
significantly alter the EAR, LAR or allergen induced increase in airway responsiveness to 
methacholine 24 hours post allergen challenge  [Hui  et al., 1991].  The negative results may 
have been due to the small sample size or, as shown by Hasday et al., [2000] the subjects studied 
could all have been low leukotriene producers.  In the Hasday paper, there was a significant 
difference in response to zileuton which was dependent on the magnitude of the increase in 
leukotrienes produced following allergen challenge.  High leukotriene producers had a better 
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response to zileuton than low producers.  Zileuton has been shown to be beneficial with respect 
to asthma control and exercise induced asthma [Israel et al., 1996; Meltzer et al., 1996]. 
   
2.3.4.2 Leukotriene receptor antagonists 
 
        Antagonists of cysteinyl leukotriene receptors have quickly been 
recognized as effective therapeutic agents in asthma management.  As with most drug classes, 
individual drugs vary with respect to potency, selectivity, and safety profile.  In that regard, 
montelukast, as opposed to pranlukast or zafirlukast, has emerged as the frontrunner in this class.  
 
 2.4 Montelukast 
 
  2.4.1 General Information 
  
   In Canada, two leukotriene receptor antagonists are available, montelukast 
which received approval from Health Canada in 1998, and zafirlukast which received approval in 
1997. Both drugs are indicated for use in asthma and have been shown to improve various 
parameters of lung function such as FEV1 and peak expiratory flow rate (PEFR), as well as 
decrease the need for rescue medication (e.g., 2 agonist), and lower the required dose of inhaled 
steroid.  Montelukast is also indicated for use in aspirin sensitive asthmatics, can be used in 
individuals who experience exercise induced bronchoconstriction and is effective in treating 
seasonal allergic rhinitis.  Montelukast is well tolerated and has a superior safety profile 
compared to zafirlukast.  The recommended dose for adults is 10 mg once per day. 
 
  2.4.2 Mechanism of action and PK/PD properties 
 
   Montelukast is a competitive antagonist at the CysLT1 receptor inhibiting 
the physiological responses normally produced by the interaction of the cysteinyl leukotrienes 
(LTC4, LTD4 and LTE4) with the CysLT1 receptor.  The structure of montelukast is provided in 
figure 2.4. Peak plasma concentrations occur at approximately 3 hours, the drug is highly bound 
to plasma proteins (>99 %) and has a half life ranging from 2.7 to 5.5 hours.  Montelukast is 
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extensively metabolized by the cytochrome P450 enzymes CYP 3A4 and 2C9 and is excreted 
mainly in the bile. 
 
     
   Figure 2.4 Chemical structure of montelukast. 
 
2.4.3 Effects of montelukast in asthma 
   
   Current guidelines (GINA 2008) now include leukotriene modifiers as add 
on therapies in the treatment of asthma in individuals who are poorly controlled on beta agonist 
monotherapy.   Similarly, individuals already on rescue bronchodilator and low dose ICS may 
increase the dose of ICS or add an LTRA to gain control.  These recommendations follow 
evidence of reduced bronchodilator use and improvement in spirometric parameters (e.g., FEV1, 
PEFR), in symptom scores, and in quality of life following LTRA treatment [reviewed by Blake, 
1999]. 
 
  2.4.4 Effects of montelukast on immune and inflammatory responses 
   
   The role of LTRA’s as modulators of immune and inflammatory responses 
is an area of considerable interest.  The clinical benefits of montelukast on allergic rhinitis and 
on the various asthma phenotypes (e.g., chronic persistent, allergen induced, aspirin sensitive 
etc.) in combination with the inflammatory components of these conditions suggest that 
leukotrienes, and therefore, leukotriene receptor antagonists are involved in immune and 
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inflammatory pathways.  As with desloratadine, much of our current understanding of the role of 
montelukast in regulating these responses comes from animal and ex vivo data.  
 
   In ovalbumin (OVA) sensitized Brown Norway rats, montelukast 
administered pre-challenge, was shown to significantly decrease eosinophil recruitment and the 
number of IL-5 positive cells in both bronchoalveolar lavage (BAL) fluid and lung tissue [Ihaku 
et al, 1999]. Pretreatment with montelukast for fifteen minutes inhibits platelet activating factor 
(PAF) induced eosinophil transmigration in human umbilical vein endothelial cells (HUVEC) 
whether stimulated with granulomonocyte colony stimulating factor (GM-CSF) and/or 
interleukin 13 (IL-13) or not [Virchow et al., 2001].   In a chronic model of inflammation, OVA 
sensitized Balb/c mice periodically exposed to OVA over 61 days, montelukast significantly 
decreased eosinophilia, mucus plugging, smooth muscle hyperplasia and sub-epithelial fibrosis 
with additional inhibitory effects on the levels of IL-4 and IL-13 [Henderson et al, 2002].  Again 
in OVA sensitized Balb/c mice (all male), montelukast (3 mg/kg and 10 mg/kg) was shown to 
inhibit airway eosinophilia and airway hyperresponsiveness (AHR) post challenge.  The authors 
also documented lower levels of IL-5 post challenge in the 10 mg/kg group but not in the 3 
mg/kg group and neither group altered eotaxin levels [Eum et al., 2003].  In keeping with high 
dose effects, 25 mg/kg montelukast in the Balb/c mouse model significantly decreased IL-4, 5, 
13 and VCAM-1 in the lung, IL-4 and 5 in BAL, IL-5 and IgE in serum, and BAL eosinophil 
counts.  High dose montelukast did not alter eotaxin levels or eotaxin mRNA expression in this 
model [Wu et al., 2003].  Conversely, however, both montelukast and pranlukast have been 
shown to block eotaxin production from human fetal lung fibroblasts primed with IL-13 and 
activated by LTC4 [Chibana et al., 2003].  In a murine model of chronic asthma (C57BL/6), 6 
mg/kg montelukast for 20 days significantly decreased BAL and tissue eosinophilia, suppressed 
the allergen induced increase in BAL IL-5 and decreased CysLT1 receptor expression [Zhang et 
al., 2004].  T cells selected from healthy and atopic donors have low levels of CysLT receptor 
expression which, for both CysLT1 and CysLT2 receptors, is increased following anti-CD3+ 
stimulation, a response that is blocked by pretreatment with montelukast resulting in T cell death 
possibly through the up-regulation of apoptotic genes such as p53 and down-regulation of 
proliferative genes such as Bcl-2 [Spinozzi et al., 2004]. Montelukast may also exert its effects 
via the downregulation of LPS induced pro-inflammatory mediators such as IL-6, TNF- and 
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MCP-1 through the inhibition of NFB activation as has been shown in THP-1 cells [Maeba et 
al., 2005]. A recent ex vivo investigation documented an upregulation of CysLT1 receptor 
expression on B lymphocytes following exposure to combined anti-CD40 and IL-4 which 
resulted in a subsequent increase in responsiveness to LTD4 as evidenced by elevated 
intracellular calcium concentrations which ultimately resulted in greater IgE and IgG production 
and was shown to be completely blocked by montelukast [Lamoureaux et al., 2006]. Eosinophils 
from healthy donors incubated in the presence of montelukast show a reduction in binding to 
intercellular adhesion molecule 1 (ICAM-1) in response to LTD4 and a decrease in adhesion in 
response to IL-5 [Kushiya et al., 2006].   In OVA sensitized guinea pigs, 0.9 mg/kg and 3 mg/kg 
montelukast administered intragastrically 2 h prior to allergen challenge prevented the decrease 
in IL-10 and inhibited the increase in NFB which may explain the documented decrease in both 
blood and BAL eosinophils at these same doses.  A lower dose of 0.3 mg/kg was ineffective on 
these same parameters [Wu et al., 2006].  Another recent investigation in C57BL/6 showed an 
inhibitory effect on allergen induced increases in both IL-11 protein and mRNA expression 
following the administration of montelukast (5 mg/kg/day x 10 days).  Similar effects were 
shown for NFB [Lee et al., 2007].   
 
   Importantly, human model investigations have also documented the anti-
inflammatory effects of montelukast.  In a four week parallel study of once daily montelukast 
versus placebo, both sputum and peripheral blood eosinophil counts were significantly decreased 
in adults with chronic asthma [Pizzichini et al., 1999].   This was reproduced later, in a separate 
4 week investigation of once daily montelukast, in mild to moderate asthma. [Minoguchi et al., 
2002].  In a 6 week double blind, parallel group study of children aged 6-18 years, montelukast 5 
mg/day or 10 mg/day, depending on age, significantly improved symptom scores and percent 
predicted FEV1 and decreased levels of IL-4, sICAM-1, ECP and peripheral eosinophil counts 
[Stelmach et al., 2002].  This same group also reported increased IL-10 following 4 weeks of 
once daily montelukast (5mg/day or 10mg/day) in children aged 4-16 years.   This effect was 
again shown by these authors using peripheral blood mononuclear cells (PBMC) from 
monoallergic grass pollen and monoallergic dust mite sensitive atopic asthmatics.   The effect in 
the monoallergic grass pollen group was observed only when testing occurred during the grass 
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pollen season and only when the PBMC were stimulated with the sensitizing allergen [Stelmach 
et al, 2005].    
 
   As discussed in Section 1.4.5 leukotriene receptor antagonists, including 
montelukast, have proven efficacious in blocking both the EAR and the LAR.  The data from the 
inflammatory and immunomodulatory investigations set out above suggests that the clinical 
benefit, with respect to the LAR in particular, results from actions that extend beyond direct 
cysLT1 receptor antagonism on airway smooth muscle cells and the inhibition of eosinophil 
recruitment and may result from the down regulation of Th2 cytokines (i.e., IL-4, IL-5, IL-13) 
possibly through the inhibition of NFB. 
 
2.5 Investigations of anti-leukotriene and anti-histamine treatment as 
monotherapy and combination therapy 
 
  2.5.1 In vitro  
  
   Reports of tissue investigations into the effect of the combination of an 
anti-histamine and a leukotriene antagonist on antigen induced contractility date back at least 
thirty years when it was shown that pretreatment of guinea pig tracheal tissue with 
diphenhydramine plus FPL-55712, a leukotriene antagonist, decreased antigen induced 
contractility better than either drug administered alone (Adams and Lichtenstein, 1979).   This 
study also showed that histamine release was initiated within minutes following exposure, was 
maximal at 10 minutes and produced a response that lasted, on average, 81 minutes. Pretreatment 
with diphenhydramine was shown to suppress the initial phase of the response.   In human 
bronchial tissue the response was somewhat similar.  Maximal histamine release occurred at 20 
minutes and produced a prolonged and sustained contraction that, on average, lasted 140 
minutes.  Diphenhydramine pretreatment was also effective in inhibiting the initial response.  In 
guinea pig, FPL-55712 pretreatment dose dependently decreased the duration of the response but 
had no effect on the development of the response. In human tissue, if FPL-55712 was 
administered after the response was initiated, the tissue relaxed and recovery to baseline tension 
occurred earlier.  This was not evident after treatment with anti-histamine.  These observations 
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led to the conclusion that both histamine and the leukotrienes were involved in the contractile 
response to antigen of guinea pig tracheal tissue and human bronchial tissue.  Furthermore, it 
appeared that histamine was responsible for initiating the response (i.e., contraction) whereas the 
leukotrienes were predominantly responsible for sustaining the contraction.  
 
   Years later, as newer leukotriene receptor antagonists were developed, 
additional studies again showed, in both guinea pig and human tissues, that the combination of 
an LTRA (SK&F 104353) with an H1 blocker (SK&F 93944 a.k.a temalastine or mepyramine) 
was more effective in blocking antigen induced contractility than either agent alone (Hay et al., 
1987).   As was documented by Adams and Lichtenstein [1979], the LTRA SK&F 104353 did 
not affect the initiation of the contraction but partially inhibited the duration of the contraction.  
Both temalastine and mepyramine inhibited the initial phase of the response in guinea pig tissue 
but, unlike the earlier study, had no effect on the initiation of the contraction in human bronchial 
tissue. 
 
   The first investigation of the effect of combining anti-leukotrienes with 
anti-histamines to inhibit IgE stimulated contractions of human bronchi, in the absence of other 
potential inhibitors (e.g., meclofenamic acid) came from researchers at the Karolinska Institute in 
Stockholm, Sweden (Bjorck and Dahlen, 1993).  This in vitro investigation used normal 
bronchial tissue obtained from individuals undergoing surgery for pulmonary carcinoma and 
included tissue from both non-asthmatic as well as asthmatic patients.  Bronchial strips were 
placed in organ baths and subjected to increasing concentrations of anti-IgE in the presence and 
absence of various compounds including an H1 receptor antagonist (mepyramine) and an H2 
receptor antagonist (metiamide), three leukotriene receptor antagonists (L-648,051, ICI 198,615 
and SKF 104353), two leukotriene synthesis inhibitors (MK886 and U-60,257 (a.k.a piriprost)), 
a thromboxane agonist (U-44,069) and the platelet activating factor antagonist WEB 2086.  Their 
work resulted in numerous observations regarding the effects of these agents on bronchial 
contractility.  First, bronchial relaxation following IgE mediated contraction is minimal with the 
addition of anti-histamines (H1 in combination with H2) but can reach 80% when pretreated with 
an LTRA (60% for L-648,051 and 80% for SKF 104353).  Combining both histamine (H1 and 
H2) blockers with L-648,051 resulted in a 100% relaxation after 21 minutes.   Second, 
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pretreatment with the various agents produced a variety of responses ranging from no effect with 
the combination of mepyramine and metiamide to complete inhibition of IgE mediated bronchial 
contraction when the anti-histamines were combined with the leukotriene antagonist ICI 198,615 
(Table 2.2). 
 
Table 2.2: In vitro effects of various drugs and drug combinations on bronchial contractility. 
TREATMENT 
MEP 
+ 
MET 
L-
648,051 
FPL 
55712 
U-60,257 MK-886 Indomethacin 
ICI 
198,615 
ICI 
198,615 
 + MEP 
+ MET 
EFFECT 
No 
effect 
~ 50% 
inhibition 
~ 50% 
inhibition 
~ 50% 
inhibition 
~ 70% 
inhibition 
No effect 
~ 65% 
inhibition 
Complete 
inhibition
MEP = mepyramine; MET = metiamide 
 
  Third, the Schultz-Dale response (i.e., IgE mediated antigen induced 
contraction) in tissue from atopic asthmatics (n=2) was completely inhibited when pretreated 
with ICI 198,615 in combination with the H1 antagonist mepyramine providing evidence to 
suggest that blocking the effects of leukotrienes and histamine in atopic asthma should be a 
useful therapeutic strategy. 
 
   A more recent in vitro investigation by Ruck et al [2001] using a different 
LTRA (MK-571) and different anti-histamine (chlorpheniramine) supported the work by Bjorck 
and Dahlen.   Cryopreserved human bronchial tissue isolated from lungs donated to the 
International Institute for the Advancement of Medicine (Scranton, PA, USA) was pretreated for 
30 min with either MK-571, chlorpheniramine or the combination and then exposed to anti-
human IgE antibody.  The combination produced a synergistic (87 %) inhibition of the 
contraction whereas inhibition with monotherapy was only 15 % following chlorpheniramine 
treatment and 36 % following MK-571 treatment.   Additionally, MK-571 did not affect 
histamine stimulation, and the anti-histamine did not affect LTD4 stimulated contractions.  
Furthermore, neither monotherapy or the combination had any influence on histamine release 
from passively sensitized human umbilical cord blood mast cells. 
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2.5.2 In vivo 
 
   In spite of the positive preclinical in vitro data on the effect of combining 
an H1 blocker with a leukotriene receptor antagonist on airway contractility, there is relatively 
little in the literature investigating the clinical effects of such a combination in individuals with 
atopic asthma.  In fact, some of the early pre-market clinical investigations of leukotriene 
antagonists showed little potential as therapeutic agents in the management of atopic asthma.  L-
649,923 was one of the first compounds to be clinically investigated as an LTD4 receptor 
antagonist.  In normal subjects, L-649,923 shifted, to the right, the dose response curve to 
exogenous LTD4 3.8 fold [Barnes et al, 1987]. However, in atopic asthmatics with dual 
responses to allergen, L-649,923 failed to show any effect on the LAR and produced only a small 
improvement in the decrease in FEV1 over the course of the EAR [Britton et al, 1987]. These 
observations suggest either that L-649,923 is not potent enough to block the effects of 
endogenous LTD4, or that LTD4 is not an integral mediator in the airway response to allergen 
exposure in atopic asthma.  A few years later, a similar compound, L-648,051 administered by 
inhalation to healthy males, was shown to partially inhibit LTD4 induced bronchoconstriction 
and to improve recovery time from bronchoconstriction [Evans et al, 1989].  In atopic asthma 
patients however, it had a minimal effect on the early response, no effect on the late response and 
produced no improvement with respect to recovery from antigen induced bronchoconstriction 
[Rasmussen et al, 1991].   The authors concluded that LTD4 was involved in the manifestation of 
the EAR.  Despite some of the early equivocal results, a number of LTRA compounds were in 
development at that time.  These included ICI-204,219 (zafirlukast), SR2640, SK&F 104353, 
MK-571, RG 12525, ONO-1078 (pranlukast), MK-679, Bay x 7195, MK-476 (montelukast), Ro 
245913 (cinalukast), and clinical trials were being carried out to assess efficacy, safety and 
tolerability in a variety of indications including asthma, atopic asthma, exercise induced 
bronchoconstriction (EIB) and aspirin induced asthma.   Trials with ICI-204,219 provided the 
first solid clinical evidence of the ability of an oral LTRA to alter the airway response to inhaled 
allergen.  The first of three investigations of ICI-204,219 was a placebo controlled crossover 
design that looked at the effect of a single 40mg dose of ICI-204,219 administered orally 2 hours 
prior to allergen challenge in 10 asthmatic subjects with allergen induced asthma.  Both the EAR 
(0-2h) and LAR (2-6h) were significantly suppressed following active treatment and the results 
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were published in the Lancet in 1991. [Taylor et al, 1991].  The second investigation confirmed 
significant inhibition of the airway responses to inhaled allergen following a single 40mg dose of 
ICI 204,219 [Findlay et al, 1992] and the third study documented the inhibitory effects of ICI-
204,219 on the EAR following a single administration of half the previous dose (i.e., 20mg) 
[Dahlen et al, 1994].   Similar results were subsequently documented for other agents in this 
class, including Bay x 7195, pranlukast and montelukast [Boulet et, 1997; Hamilton et al, 1998; 
Diamant et al, 1999].  We can conclude from these investigations that LTRA’s are efficacious in 
blocking the airway response to inhaled allergen, but the inhibition is suboptimal, approximately 
75 % for the EAR and approximately 50 % for the LAR.   
 
   The clinical effects of antihistamine monotherapy on airway responses to 
inhaled allergen are not so clear.  First generation histamine H1 receptor antagonists such as 
clemastine (1 mg) and ketotifen (2 mg) have failed to alter the airway response to inhaled 
allergen in vivo [Cockcroft et al, 1992].  Conversely however, azelastine has been shown to 
inhibit the EAR FEV1 AUC by 32.5  % and the LAR FEV1 AUC by 70.2 % [Rafferty et al, 
1989].  Terfenadine has also been shown to inhibit both the mean maximal fall in FEV1 during 
the EAR (from 33.2 to 20.3 %) and the mean maximal fall in the peak expiratory flow rate 
(PEFR) during the LAR (from 22.6 to 15.2 %) [Hamid et al, 1990]. The azelastine and 
terfenadine investigations may however be limited in that the sample sizes of 5 and 7 are small 
and the overall power of the study (< 70 %) is less than the generally accepted level of 80 % or 
higher.  It is also unclear, with respect to the terfenadine study, why the LAR would be reported 
as a change in PEFR versus FEV1 which is commonly used and, interestingly, was used for the 
analysis of the EAR.  It is worth noting that terfenadine was withdrawn from the market due to 
cardiac toxicity and replaced by its metabolite fexofenadine.  Although not studied in humans, 
there are data to suggest that fexofenadine modulates T cell function in a murine model of 
allergen induced airway inflammation and hyperresponsiveness [Gelfand et al, 2002; Gelfand et 
al, 2003].  Also worth noting is that the inhibitory effect of azelastine on the EAR was later 
confirmed in a randomized, placebo controlled, double blind study in ten subjects with atopic 
asthma pretreated for 4 days with azelastine [Twentyman et al, 1993].   Soon after however, the 
second generation anti-histamine, loratadine, was reported to have no significant effect on either 
the EAR or the LAR following once daily administration for 3 days [Town and Holgate, 1990].  
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Negative results have also been shown following oral or inhaled cetirizine [Rafferty et al, 1993] 
which were later confirmed following 18 days of 30 mg per day cetirizine [de Bruin-Weller et al, 
1994].  
 
   We can conclude from the literature that from 1979 through 1994 there 
were limited clinical investigations that produced equivocal results of the effects of CysLT1 and 
H1 antagonism on the early and late airway responses to inhaled allergen in individuals with 
atopic asthma.  Drug development with both classes has subsequently produced potent and 
selective compounds that are effective in asthma (e.g., zafirlukast and montelukast) and allergic 
rhinitis (e.g., loratadine, desloratdine) which may have been the impetus, together with the 
relatively strong theoretical basis and preclinical data of these newer agents, to revisit the 
hypothesis of a superior efficacy in the combined treatment of atopic asthma. 
 
   The first study to re-examine this hypothesis documented a 74 % 
reduction in the maximal fall in FEV1 during the EAR and a 48 % reduction in the maximal fall 
in FEV1 during the LAR following one week of high dose combination therapy using 80 mg bid 
zafirlukast and 10 mg bid loratadine [Roquet et al, 1997].   Expressed as FEV1 AUC the 
combination produced an inhibitory effect on the EAR of 75 % and on the LAR of 74 %.  The 
changes for all active treatments, whether expressed as the maximal fall in FEV1 or FEV1 AUC 
were all significantly different compared to control challenges.  Of particular interest however 
are the comparative results between the monotherapies and the combination.  Regardless of the 
parameter used for assessment, the combination was significantly better than either single 
treatment during the LAR, but did not produce greater inhibition than that of zafirlukast during 
the EAR.  This was the first clinical evidence to compare the effects of an antihistamine with that 
of a leukotriene receptor antagonist and assess combined mediator blockade on the response to 
inhaled allergen in a bronchoprovocation model.   The lack of superior combined efficacy on the 
EAR as well as the significantly different inhibition with combined therapy on the LAR would 
not have been expected.  Surprisingly, in the last eleven years, only one subsequent investigation 
of combined antihistamine, antileukotriene treatment on the allergen induced EAR and LAR 
could be identified [Richter et al, 2008].  The authors showed that the combination of one week 
of clinically recommended doses of azelastine (4 mg bid) and montelukast (10 mg qd) 
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significantly decreased the maximum fall in FEV1 during the EAR and LAR compared to either 
therapy alone.  Furthermore, both montelukast and azelastine significantly decreased the EAR 
and montelukast was superior to azelastine in that regard.  Azelastine and montelukast also 
decreased the LAR but there was no difference between the two.  These results are similar to 
what was shown in the Roquet et al., [1997] study providing further evidence that these types of 
drugs provide superior efficacy when administered in combination.   
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3.0 STATEMENT OF OBJECTIVES AND HYPOTHESES 
 
 3.1  Early Asthmatic Response Objective 
 
  The purpose of the early response investigation was to prospectively assess the 
effect of the combination of desloratadine and montelukast on the allergen induced early 
asthmatic response in a cohort of patients with mild atopic asthma. 
  
3.2  Early Asthmatic Response Hypothesis 
  
  The hypothesis is that the combination of desloratadine and montelukast provides 
better protection against the EAR than either drug administered alone. 
 
Null Hypothesis: H0: Placebo = Desloratadine = Montelukast = Combination 
Alternative Hypothesis: H1: Placebo < Desloratdine < Montelukast < Combination 
  
3.3 Late Asthmatic Response Objective 
   
  The purpose of the late response investigation was to prospectively assess the 
effect of the combination of desloratadine and montelukast on the allergen induced late asthmatic 
response and related sequelae. 
 
 3.4 Late Asthmatic Response Hypothesis 
   
  The hypothesis is that the combination of desloratadine and montelukast provides 
better protection against the LAR and related sequelae than either drug administered alone in a 
cohort with mild atopic asthma and DAR following allergen exposure. 
 
Null Hypothesis: H0: Placebo = Desloratadine = Montelukast = Combination 
Alternative Hypothesis: H1: Placebo < Desloratdine < Montelukast < Combination 
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4.0  EFFECT OF COMBINED MONTELUKAST AND DESLORATADINE ON THE 
 EARLY ASTHMATIC RESPONSE TO INHALED ALLERGEN 
 
 4.1 RELATIONSHIP TO THESIS 
 
  This chapter addresses the objective and hypothesis stated in sections 3.1 and 3.2 
respectively.  More specifically, this chapter deals with the investigation of the effect of 
combined montelukast and desloratadine on the early asthmatic response to inhaled allergen.  
This work was published in the Journal of Allergy and Clinical Immunology (Appendix A).   
 
 4.2 ABSTRACT 
 
 The early asthmatic response to inhaled allergen results from IgE-mediated 
release of multiple mast cell mediators, including leukotrienes and histamine; both of which 
cause bronchoconstriction.  Combination therapy directed at blocking the effects of both 
mediators may protect against the early asthmatic response better than either therapy alone. 
 
 We investigated the combination of montelukast and desloratadine on the EAR to 
inhaled allergen using the standardized allergen challenge model in ten mild atopic asthmatics 
with a four way cross over, randomized, double blind, placebo controlled design.   
 
 Desloratadine did not protect against allergen induced bronchoconstriction 
whereas montelukast and the combination of montelukast and desloratadine both significantly 
increased the allergen PC20 compared to placebo (p<0.001).  Furthermore, the combination of 
montelukast and desloratadine provided superior protection against allergen induced 
bronchoconstriction than that of montelukast monotherapy (p=0.02).   
 
 We provide evidence that clinical doses (10 mg montelukast and 5 mg 
desloratadine) administered in combination at 26 hours and 2 hours prior to allergen inhalation 
challenge significantly and synergistically inhibit the EAR. 
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 4.3 INTRODUCTION 
 
 The response of the airways to inhaled allergen in individuals with atopic asthma  
is an  IgE-mediated mast cell degranulation process leading to the early asthmatic response 
(EAR) which peaks about 15-30 minutes post inhalation and is often followed by a late asthmatic 
response (LAR) developing 3-8 hours post inhalation.  The degranulation process results in the 
release of multiple mediators, including the leukotrienes and histamine.  The EAR is thought to 
be due to airway smooth muscle contraction, mediated in part by histamine on H1 receptors and 
leukotrienes on CysLT1 receptors.  It follows that blocking the activity of these mediators may 
prevent bronchoconstriction.  Investigations of the effect of H1 blockers on the EAR have 
produced variable and inconclusive results [Rafferty et al., 1987; Gong et al., 1990; Rafferty et 
al., 1990; Cockcroft et al., 1992; Bentley et al., 1996].  Leukotriene modifiers have been shown 
to provide reasonable inhibition of the EAR and LAR but do not completely abolish the response 
[Dahlen et al., 1991; Taylor and O’Shaughnessy, 1991; Diamant et al., 1995; Hamilton et al., 
1997; Hamilton et al., 1998].  The idea that a mechanism involving multiple mediators may 
require multiple interventions continues to attract interest in the role of combination therapies for 
the treatment of atopic asthma.  Desloratadine is an antihistamine that has not been clinically 
investigated in atopic asthma and the response to inhaled allergen.  Montelukast is effective in 
partially attenuating the response to inhaled allergen.  There are no published data reporting the 
effect of the combination of these two therapies on allergen induced airway responses. 
 
4.4 METHODS 
 
  4.4.1 Subjects 
 
  Ten healthy atopic asthmatics aged 18 years or older with a baseline FEV1 
 65% predicted participated in the study (Table 4.1).  Subjects had no respiratory infection or 
allergen exposure for at least four weeks prior to enrolment. The protocol was approved by the 
University of Saskatchewan Biomedical Ethics Research Board and subjects provided written 
consent prior to any procedures being conducted. (Appendix B). 
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  Salbutamol (n=10) was withheld prior to testing for at least 8 hours.  
Fluticasone was used (stable dose for 3 months) by one subject. No subjects used any other 
asthma therapies or antihistamines. 
 
  4.4.2 Study Design  
 
  This was a randomized, four way crossover, placebo controlled (thiamine 
100 mg) investigation.  A study flowchart is included as Appendix C.  Matching placebo tablets 
were unavailable.  Subjects were provided with two small brown envelopes containing either two 
placebo tablets; one desloratadine tablet (5 mg) and one placebo tablet; one montelukast tablet 
(10 mg) and one placebo tablet; or one desloratadine tablet and one montelukast tablet.  Subjects 
were instructed to ingest the contents, without looking at it, of one envelope 26 hours, and the 
other 2 hours prior to allergen challenges which were scheduled at least 7 days apart.  No subject 
had previously used desloratadine and only one subject had previously used montelukast.  The 
investigator was blind to the treatments.   
 
  4.4.3 Allergen Challenges  
 
  Subjects were challenged during the non-pollen season (i.e., December 
through March) with the allergen that produced the largest response on skin prick testing.  Serial 
2-fold dilutions were prepared from 1:8 stock solutions diluted with sterile isotonic saline 
containing 0.4 % phenol.  Starting concentrations for inhalation were determined with the use of 
an algebraic prediction of allergen PC20 using skin test endpoint and airway responsiveness to 
methacholine [Cockcroft et al., 1997].  Allergen challenges began with the same concentration 
for each individual on each occasion.  Allergens (Western Allergy Services, Victoria, BC; see 
Table 4.1) were aerosolized via a Wright Nebulizer (Roxon Medi-tech Ltd., Montreal, PQ) 
calibrated to deliver 0.13 mL/min.  Each concentration was inhaled during two minutes of tidal 
breathing via a mouthpiece and with nose clips in place.  Ten minutes after each inhalation was 
completed, two technically acceptable FEV1 maneuvers were performed sixty seconds apart.  
Inhalations were continued until the highest post inhalation FEV1 was at least 15 % lower than 
the highest baseline FEV1 (obtained from three reproducible flow volume loops after a  20 
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minute rest period) or until the top concentration had been administered.  The FEV1 was repeated 
at 10 minute intervals until no further decrease was observed [Cockcroft and Murdock, 1987].  
The allergen PC20 was then calculated algebraically [Cockcroft et al., 1983].  Salbutamol (200 
g) was administered to reverse the acute bronchoconstriction.  Fluticasone (500 g) was 
administered to prevent the late response and associated increase in airway responsiveness 
[Cockcroft et al., 1993].  
 
  4.4.4 Data Analysis 
 
  Baseline FEV1 data and log transformed allergen PC20 data were analysed 
by 2 way ANOVA followed by pairwise comparison (least squared difference, (LSD)) of means 
if applicable (Statistix Version 7.0, Tallahassee, FL).  Power calculations indicated a 98 % power 
to detect a one doubling concentration difference in  allergen PC20 in 10 subjects and a 97 % 
power in 9 subjects. 
 
4.5 RESULTS 
 
All ten subjects completed the study with no adverse events.  A post hoc decision 
to exclude data of one subject (#10) was made based on the observation that the screening 
allergen challenge and the placebo treatment allergen challenge were not reproducible.  The 
overall significance of the data was not affected.   
 
 Mean baseline FEV1 (litres  SD) measurements following placebo (3.24  0.55), 
desloratadine (3.25  0.54), montelukast (3.27  0.54) and the combination (3.31  0.57) were 
not significantly different from each other (ANOVA p = 0.19). 
 
 Comparison of geometric mean allergen PC20 (units/mL) differences between 
combination (697), montelukast (338), desloratadine (123) and placebo (104) treatments was 
highly significant (ANOVA p<0.00001; Figure 4.1).  The mean log values ( SEM) following 
combination, montelukast, desloratadine and placebo treatments were 2.8433 (0.3253) 2.5295 
( 0.2979), 2.0883 ( 0.2102) and 2.0166 ( 0.2553) respectively.  Compared to placebo (LSD 
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comparison of means) combination therapy and montelukast therapy significantly increased 
allergen PC20 (p < 0.001 for both).  Allergen PC20 with combination therapy was significantly 
greater than with montelukast alone (p=0.02) and montelukast alone was significantly greater 
than with desloratadine alone (p<0.002).   Desloratadine and placebo treatments produced similar 
results (p > 0.2).  Analysis of individual fold increases in allergen PC20 (combination vs placebo; 
montelukast vs placebo and desloratadine vs placebo) indicated mean fold increases of 8.9, 4.8 
and 1.4 fold or 3.2, 2.3, and 0.49 doubling concentrations respectively.   
 
4.6 DISCUSSION 
 
 We have demonstrated that 5 mg of desloratadine administered 26 hours and two 
hours prior to allergen inhalation does not protect against the EAR.  We have also demonstrated 
that 10 mg of montelukast administered 26 hours and two hours prior to allergen inhalation 
increases allergen PC20 2.3 doubling concentrations while the combination increases allergen 
PC20 3.2 doubling concentrations. 
 
 Desloratadine is the principal metabolite of the second generation antihistamine 
loratadine.  Although loratadine had previously been shown to be ineffective in decreasing the 
EAR [Town and Holgate, 1990], desloratadine possesses superior pharmacokinetic and 
pharmacodynamic properties; has an excellent safety profile; and has been shown to exert anti-
inflammatory effects [Murdoch et al., 2003].  The lack of efficacy following desloratadine 
therapy reported here suggests that desloratadine alone does not protect against the EAR by 
blocking H1 receptors on airway smooth muscle. 
 
 Montelukast is a leukotriene receptor antagonist with proven efficacy in asthma 
and exercise-induced bronchoconstriction [Blake, 1999] and has been shown to significantly 
decrease the EAR to inhaled allergen [Diamant et al., 1999; Leigh et al., 2002; Palmqvist et al., 
2005].  Our data are consistent with the existing literature on the effect of montelukast on the 
EAR, although we do show a slightly greater inhibition of the EAR after montelukast when 
changes in the maximal decrease in FEV1 are equated to changes in doubling concentrations.   In 
our study, montelukast shifts the dose response curve versus placebo more than 2 doubling 
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concentrations.  This is equivalent to a 75 % decrease (versus an average of around 55 % 
reported previously [Diamant et al., 1999; Leigh et al., 2002; Palmqvist et al., 2005]) in the 
maximal fall in FEV1. 
 
 It is logical to postulate that the EAR to inhaled allergen could be additively or 
synergistically blocked by combining CysLT1 and H1 receptor antagonist therapies.  This effect 
was demonstrated in vitro more than ten years ago in isolated human bronchi [Bjorck and 
Dahlen, 1993].  Since then, only two studies investigating the effect of combining an 
antihistamine with an LTRA on the EAR could be identified. Roquet et al., [1997] investigated 
the combination of high dose zafirlukast (80 mg bid) and loratadine (10 mg bid) administered for 
seven days on the EAR and LAR and found that combination therapy was more effective at 
inhibiting the EAR than either drug alone however, the difference between the inhibition 
following zafirlukast was not significantly different from the inhibition following combination 
therapy.  A more recent in vitro investigation of the H1 anti-histamine chlorpheniramine and the 
LTRA MK-571 documented a synergistic effect of the combination versus either drug alone in 
allergic isolated human bronchi [Ruck et al., 2001].  We could identify no published data 
describing the effect on allergen induced airway responsiveness following montelukast in 
combination with an antihistamine. 
 
 We provide evidence that the combination of 5 mg of desloratadine with 10 mg of 
montelukast administered at 26 hours and 2 hours prior to allergen inhalation increases allergen 
PC20 3.2 doubling concentrations (8.9-fold) versus placebo.  This is the first evidence of 
clinically significant inhibition of the EAR using clinically relevant doses of the combination of 
an antihistamine and an LTRA that is significantly greater than the inhibition afforded by LTRA 
monotherapy.  Since no effect was observed with desloratadine alone, the significantly greater 
combined efficacy is difficult to interpret.   The magnitude of inhibition is similar to that 
achieved with 10 mg inhaled sodium cromoglycate (76 %), lower than 200 g salbutamol (97 %) 
and substantially greater than single dose (200 g) beclomethasone dipropionate (< 1 %) 
reported as maximal decreases in FEV1 [Cockcroft et al., 1987] suggesting mast cell stabilization 
as a  possible mechanism.  
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 There are several methods to assess the EAR including AUC (0-3h), maximal 
decrease in FEV1, and allergen PC20. These differences in methodology present difficulties in 
data comparison and reinforce the issue of method standardization.  Efficacy reported as AUC 
(0-3h) represents changes in the airway that are occurring over 180 minutes, 2/3 of which 
represents the spontaneous recovery portion of the EAR and 1/3 of which represents the 
development of and the maximal response to the sensitizing agent.  Comparison of AUC (0-3h) 
data with data reported as changes in the maximal decrease in FEV1 or allergen PC20, both of 
which measure changes occurring in the first 60 minutes, is therefore extremely difficult.  
Reporting the EAR as maximal changes in FEV1 requires the same dosing regimen and 
occasionally single dose administration of allergen.  Although single dose administration 
protocols may raise concerns surrounding subject safety, the change in maximal decrease in 
FEV1 can, at least in theory, be compared with the algebraic determination of allergen PC20.  
Assuming a linear dose response, we estimate that a shift of one doubling concentration is 
approximately equivalent to a 50 % change in the maximal fall in FEV1; 2 doubling 
concentrations approximately a 75 % change; 3 doubling concentrations approximately 87.5 % 
change and so on.  Therefore, allergen PC20 reporting provides a more precise discrimination 
between treatments that generate a  50% change in the maximal decrease in FEV1.  The one 
major limitation to assessing airway response to inhaled allergen using this method is that it 
cannot be used to assess the LAR.  Therefore, the relevance of these data to the clinical features 
and management of asthma remain to be determined. 
 
 We present in vivo data supporting a synergistic effect of the combination of 
montelukast and desloratadine on the early response to inhaled allergen.  The mechanism(s) 
underlying the apparent synergism and the effect of the combination of montelukast and 
desloratadine on the LAR and related sequelae require further investigation. 
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Table 4.1:  EAR Study Subject Demographics 
 
Subject Gender 
Age 
(years) 
Height 
(inches)
Baseline 
FEV1 
(litres) 
Baseline 
FEV1 % 
Predicted 
Allergen 
used for 
inhalation 
MPC20 
(mg/mL) Medications
         
1 M 57 66 2.46 73 GRASSa 0.5 S; prn 
2 M 29 70 3.87 87 HDMb 2 S; prn 
3 M 27 71 3.67 86 CATc 0.67 S; prn 
4 F 24 62 2.66 83 CATc 0.28 S; prn 
5 M 25 72 4.07 85 CATc 2 S; prn 
6 M 40 72 2.86 65 GRASSa 1.8 S; prn 
7 F 25 66 3.12 89 HDMb 2.5 
S; prn         
F 125 g 
bid 
8 M 43 68 3.44 88 GRASSa 16 S; prn 
9 F 27 64 3.35 101 CATc 0.86 S; prn 
10* M 26 72 4.59 96 CATc 0.75 S; prn 
         
Mean  32 68 3.41 85  2.7  
         
* not included in analysis  
S = salbutamol   
MPC20 = methacholine 
PC20  
F = fluticasone propionate  
a:  Grass Mix 10 (40,000 protein nitrogen units/mL) 
b:  Standard Mites Mixed (10,000 allergy units/mL) 
c:  Standardized Cat Pelt (10,000 bioequivalent allergy 
units/mL) 
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Treatment
Placebo Desloratadine Montelukast Montelukast
Allergen
PC
20
(units/mL)
50
100
200
400
800
1600
+
Desloratadine
ANOVA p < 0.00001
n = 9p = 0.02
p < 0.002
 
 
Figure 4.1:  Treatment effects on the EAR allergen PC20.  
   Extract units are generically identified as units/mL.  Error bars represent  
   standard error of the mean (SEM). 
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5.0  SINGLE DOSE DESLORATADINE AND MONTELUKAST AND ALLERGEN- 
 INDUCED LATE AIRWAY RESPONSES 
 
 5.1 RELATIONSHIP TO THESIS 
 
  The following chapter addresses the objective and hypothesis stated in sections 
3.3 and 3.4 respectively.  More specifically, this chapter describes the rationale, methods and 
results and discusses the effect of single dose desloratadine and montelukast on the late asthmatic 
response and its related sequelae to inhaled allergen.  This work was published in the European 
Respiratory Journal.  The Abstract is appended. (Appendix D).   
  
 5.2 ABSTRACT 
 
 Allergen exposure in atopic asthmatics with a dual response results in two 
independent episodes of reversible airway obstruction termed the early asthmatic response 
(EAR) and the late asthmatic response (LAR).  The LAR coincides with airway eosinophilia, 
changes in responsiveness to methacholine, and increased levels of exhaled nitric oxide which 
remain evident even after FEV1 recovery (i.e., 24 hour post exposure).  There is evidence that 
montelukast suppresses the LAR but the inhibition is incomplete.  Having shown a synergistic 
effect of the combination of montelukast and desloratadine on the EAR we hypothesized that the 
combination may also be effective in protecting against the LAR and related airway changes. 
  
 Ten mild atopic asthmatics were enrolled in a 4 way crossover, randomized, 
double-blind, placebo controlled standardized LAR allergen inhalation challenge study.  
Treatment arms consisted of a single dose of montelukast (10 mg), desloratadine (5 mg), the 
combination of montelukast (10 mg) and desloratadine (5 mg) or matching placebo.  Treatments 
were administered two hours prior to allergen challenge.   
 
 The mean LAR AUC was significantly decreased for all active treatments 
compared to placebo (rank order: combination > montelukast = desloratadine > placebo).  
Desloratadine, montelukast and desloratadine in combination with montelukast also significantly 
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decreased the EAR AUC compared to placebo (rank order: combination = montelukast > 
desloratadine > placebo).  Sputum eosinophils were significantly reduced by desloratadine 
monotherapy at 7 hours and by montelukast monotherapy at 24 hours (p < 0.05).  Sputum 
eosinophils were significantly reduced by the combination of desloratadine and montelukast at 
both 7 hours and 24 hours (p < 0.05). Significantly lower levels of exhaled nitric oxide were 
observed following montelukast monotherapy only and only at the 24 hour measurement (p < 
0.05).  We observed no effect following any of the active treatments on the increased 
responsiveness to methacholine. 
 
 Single dose co-administration of desloratadine and montelukast two hours prior to 
allergen exposure clinically abolished the LAR AUC. Sputum eosinophils were fewer in number 
following desloratadine and the combination at 7 hours and montelukast and the combination at 
24 hours.  Neither the combination nor the individual therapies altered changes in responsiveness 
to methacholine although a trend toward higher methacholine PC20 values was evident following 
montelukast and the combination. Montelukast suppressed the increase in exhaled nitric oxide at 
the 24 hour time point.  No other active treatment was effective in altering exhaled nitric oxide 
levels. 
  
 5.3 INTRODUCTION 
 
 The airway response to inhaled allergen is characterized by airflow obstruction 
that is usually maximal within 20-30 minutes of exposure.  This is referred to as the early 
asthmatic response (EAR) which results from IgE mediated mast cell degranulation, release of 
stored mediators (e.g., histamine) and newly synthesized mediators (e.g., leukotrienes) which 
subsequently exert their effects on surrounding tissues causing bronchoconstriction, plasma 
exudation and mucus hypersecretion.  The late asthmatic response (LAR), which occurs in at 
least 50 % of individuals with positive allergen challenge, is a subsequent episode of airflow 
obstruction that develops over the 3-8 hours after the EAR has spontaneously resolved.  As the 
LAR develops, and for a limited time after the LAR has resolved, the airway has been invaded 
with leukocytes (eosinophils in particular), has become hyperresponsive to direct stimuli (e.g., 
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methacholine) and produces increased levels of nitric oxide, collectively termed the late 
sequelae.  
 
The mechanisms of the LAR and related sequelae remain unknown.  A predominant role 
for a Th2 cell and cytokine (IL-4, IL-5, IL-13) profile has been well established although recent 
data are challenging this ideology.  Desloratadine, the most potent metabolite of the second 
generation antihistamine loratadine and the LTRA drug of choice montelukast synergistically 
inhibit the EAR following combined use.  The magnitude of the EAR influences the LAR within 
a given subject. Animal and in vitro models have provided evidence to suggest that both these 
agents possess anti-inflammatory activity including the ability to decrease IL-4, IL-5 and IL-13 
levels.  These agents may therefore protect against the allergen induced LAR and related 
sequelae. 
 
 5.4 METHODS 
 
  5.4.1 Subjects 
 
   Potential study participants were either known dual responders or 
underwent screening allergen challenges to assess eligibility.  These individuals were recruited to 
be study subjects providing the following criteria had been met and baseline demographics are 
provided in (Table 5.1): 
 
 baseline FEV1  70 % predicted 
 methacholine PC20 ≤ 16 mg/mL 
 positive skin test to a common aeroallergen 
 EAR of ≥ 20 % fall in FEV1 and LAR of ≥ 15 % fall in FEV1 
 No respiratory infection or change in allergen exposure for 4 weeks prior to enrolment and 
throughout the investigation 
Salbutamol (n=10) was withheld prior to testing for  6 hours.  One subject was using inhaled 
corticosteroid and one was using nasal corticosteroid, both on stable dose prior to and throughout 
the study.  The protocol was approved by the Ethics Research Boards of each institution and all 
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subjects provided written consent prior to the conduct of any study related procedures (Appendix 
E). 
 
 5.4.2 Study Design  
 
   We conducted a randomized, double-blind, four-way crossover, placebo-
controlled, multicenter allergen inhalation challenge investigation. A study flow chart is included 
as Appendix F. Assessments of exhaled nitric oxide levels were performed pre allergen 
inhalation and at 4, 7 and 24 hours post allergen inhalation. Airway hyperresponsiveness to 
methacholine (i.e., methacholine challenges) were performed 24 hours prior to allergen 
challenges and 24 hours after allergen challenges.  Sputum samples were also collected 24 hours 
prior to allergen challenges and 7 hours and 24 hours after allergen challenges.  All sites used the 
same standardized methodology for all assessments.  The study was registered at 
www.clinicaltrials.gov under #NCT00424580.  The Saskatoon Health Region Pharmacy 
Research Unit at the Royal University Hospital, Saskatoon, Saskatchewan provided currently 
available tablets of desloratadine and montelukast encapsulated with lactose filler to produce 
identical looking treatments.  Individual treatments were provided to study participant on Day 1 
of each treatment arm in a sealed small brown envelope.  Study participants were instructed to 
ingest the contents of the envelope 2 hours prior to their allergen challenge visits which were 
scheduled at  10 day intervals.   
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Day 1
24 h
pre allergen
challenge
ALLERGEN CHALLENGE
Day 3
24 h
post allergen
challenge
• eNO
• MCh
• SI
DOSE
2 h pre allergen
challenge
• eNO
• MCh
• SI
EAR
(0-3h)
LAR
(3-7h)
• Placebo
• 5 mg D
• 10 mg M
• 5 mg D
+
10 mg M
Day 2
7 h
post allergen
challenge
• eNO
• SI
Day 2
eNO, exhaled nitric oxide; MCh, methacholine challenge; SI, sputum induction; EAR, early asthmatic response; LAR, late 
asthmatic response  
Figure 5.1: LAR Study Design 
4h 
eNO 
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 5.4.3 Allergen Inhalation Challenges  
 
   Serial 2-fold dilutions were prepared from standardized stock allergen 
(grass, cat and house dust mite (dermatophagoides pteronyssinus and dermatophagoides farinae) 
and diluted with normal saline.  Starting concentrations for inhalations were determined by 
algebraic prediction of allergen PC20 using the skin test endpoint and methacholine PC20 
[Cockcroft et al., 2005]. Allergen challenges began with the same concentration and the same 
number of concentrations were administered, within a given individual, for each allergen 
challenge (i.e., the same dose of allergen was administered following each treatment.)  Allergens 
were aerosolized via a Wright Nebulizer (Roxon Medi-tech Ltd., Montreal, PQ) calibrated to 
deliver 0.13mL/min.  Each concentration was inhaled over two minutes of tidal breathing via a 
mouthpiece and with nose clips in place.  Ten minutes after each inhalation was completed, two 
technically acceptable FEV1 maneuvers were performed sixty seconds apart.  Once the EAR was 
captured, the response remained untreated and the FEV1 was assessed at various standardized 
time points, up to 7 hours post allergen inhalation, to capture the LAR [Boulet et al., 2007].  The 
area under the curve (AUC) for the EAR and LAR were calculated using the trapezoid rule. 
 
 5.4.4 Methacholine Challenges 
 
   Methacholine challenges were performed 24 hours before and 24 hours 
after the allergen inhalation challenge using a standardized two minute tidal breathing method 
[Crapo et al., 1999; Cockcroft et al., 1977].  All methacholine challenges were performed in an 
identical manner (i.e., same starting concentration) within a given subject.  The PC20 was 
extrapolated if a concentration of 16 mg/mL or less resulted in a percent fall in FEV1 of greater 
than 17 % but less than 20 % [Jokic et al., 1998]; and interpolated if the percent fall was > 20% 
[Cockcroft et al., 1983].  Salbutamol (200 g) was administered at the completion of each 
methacholine challenge. 
 
 5.4.5 Sputum Collection and Analysis 
 
   Sputum was collected 24 hours pre allergen challenge, and 7 and 24 hours 
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post allergen challenge.  Sputum collection and processing was performed using the 
methodology of Pizzichini and co-workers [Pizzichini et al., 1996].  In brief, subjects inhaled, 
via mouthpiece, increasing concentrations (3 %, 4 % and 5 %, each for 7 minutes) of hypertonic 
saline, aerosolized by a high output ultrasonic nebulizer. Collected specimens were immediately 
refrigerated and processed within 2 hours of collection.  Total cell counts were determined using 
a Neubauer hemocytometer chamber (Hausser Scientific, Horsham, PA) and expressed as the 
number of cells per milliliter of sputum. Differential cell counts were performed under blinded 
conditions from cytospins stained with Diff Quik (Dade Behring, Newark, DE). 
 
 5.4.6 Exhaled Nitric Oxide  
 
   Exhaled nitric oxide measurements were collected 24 hours pre allergen 
challenge and 4, 7 and 24 hours post allergen challenge as per ATS recommendations [American 
Thoracic Society, 1999] using the Aerocrine NIOX system (Aerocrine, Solna, Sweden).  
Subjects performed an inhalation via a filter/mouthpiece to total lung capacity followed by 
exhalation at a constant flow rate of 50 mL/sec until the reading was captured.   Comparisons 
were made using the mean of three measurements at each timepoint. 
 
  
  5.4.7 Data Analysis 
 
   Two way (subject/treatment) analysis of variance (ANOVA), followed by 
pair wise comparison of means (least squared difference) if applicable (Statistix Version 7.0, 
Tallahassee, FL) was used to examine differences in the endpoints under investigation.  The 
study was appropriately powered (>80 %) with ten subjects to detect differences in the primary 
endpoint (LAR – 50 % inhibition in AUC), and in the secondary endpoints (EAR, allergen 
induced airway hyperresponsiveness and sputum eosinophil cell counts) [Inman et al., 1995; 
Gauvreau et al., 1999]. The appropriate sample size to achieve at least 80 % power in detecting a 
significant change in FeNO is unknown. 
 60
 5.5 RESULTS 
  
  All ten randomized subjects completed the study without incident.   
Desloratadine, montelukast and the combination all significantly decreased the LAR area under 
the FEV1 curve, in a treatment dependent manner (ANOVA p <0.001). Desloratadine reduced 
the response by 43 %, montelukast by 71 % and the combination completely blocked the 
response (Figure 5.2).    Desloratadine, montelukast and the combination also significantly 
reduced the mean AUC EAR by 32 %, 72 % and 100 % respectively (Figure 5.3). The inhibition 
with combination however was not significantly different from that of montelukast alone for the 
EAR (p=0.052).  The mean percent fall in FEV1 at various time points following allergen 
challenge is shown in Figure 5.4.  The doubling dose increase in methacholine PC20 was 
0.660.19 (meanSEM) after placebo; 0.820.26 after desloratadine; 0.310.21 after 
montelukast and 0.180.23 after combination (ANOVA p = 0.092; Figure 5.5).  The allergen 
induced increase in FeNO was significantly less after montelukast treatment only and only at the 
24 h time point (p = 0.03; Figure 5.6). Sputum eosinophils increased 23.2 % 7 hours post 
allergen inhalation in the untreated arm whereas the increase following desloratadine was only 
10.5 % and after combination only 2.8 % (p < 0.05).  At 24 hours post allergen challenge, the 
percent increase in sputum eosinophils was 8.8 % following montelukast and 4.5 % after 
combination as compared to 16.2 % after placebo (p < 0.05).  The difference between the 
individual therapies and combination was not significant at either time point (Figure 5.7 and 5.8).    
 
 5.6 DISCUSSION 
 
  Our in vivo investigation provides new insights into the effects of desloratadine, 
montelukast and the combination in individuals with mild atopic asthma and a dual asthmatic 
response.  Few clinical studies have investigated the effects of combining a leukotriene 
antagonist with an antihistamine on the airway response to allergen, and none have looked at a 
single dose. Loratadine, the parent compound of desloratadine, has been shown by Roquet et al., 
[1997] to significantly decrease the LAR alone and in combination with zafirlukast following 
one week of high dose therapy (twice the daily recommended dose of both drugs).  We have 
shown that desloratadine, in a single dose, provides the same magnitude of bronchoprotection 
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against the LAR as this previous study of higher dose and longer duration.  Comparison of the 
leukotriene antagonists suggests that a single dose of montelukast is also more effective than 
multiple high dose zafirlukast.  We also document a complete inhibition of the LAR with the 
combination of montelukast and desloratadine whereas the Roquet study showed only a 75 % 
inhibition of the LAR following the combination of zafirlukast and loratadine.   Similarly, a 
more recent investigation using clinically relevant doses of azelastine and montelukast for 1 
week also showed less of an effect compared with our results [Richter et al., 2008].  The 
differences between our study and these two studies may be related to the pharmacokinetic and 
pharmacodynamic (PK/PD) properties of the therapies, allergen challenge methodologies, study 
design or may even suggest the development of tachyphylaxis or the onset of tolerance following 
the longer and higher dosing regimen. 
 
  Our first investigation (i.e., Chapter 4) documented a synergistic inhibition of the 
EAR with combination therapy (8.9 fold increase in allergen PC20) which was significantly better 
than the effect of desloratadine (1.4 fold increase in allergen PC20) and montelukast (4.8 fold 
increase in allergen PC20) monotherapy.  Compared to placebo, montelukast also inhibited the 
response but desloratadine, by itself, had no effect.  We now document that a single dose of 
desloratadine, assessed as AUC, significantly inhibits the EAR, as does both a single dose of 
montelukast and the combination of desloratadine and montelukast, however, the inhibitory 
effect of LTRA monotherapy and that of the combination on the EAR AUC is not significantly 
different.  The observed differences are almost certainly not related to differences in the dose of 
active treatment (i.e., the LAR study used half the dose of that used in the isolated EAR study) 
but are probably related to the duration the response was observed and the difference in the 
amount of allergen administered.  That is, the airway response during the isolated EAR study 
was measured until the response was maximal and the FEV1 was trending upward, perhaps 45 
minutes to 1 hour post allergen inhalation.  Whereas in the LAR investigation the EAR, assessed 
as AUC, captured the maximal response as well as the recovery (i.e., 0-3 hours).  Comparison of 
isolated EAR challenge data (i.e., dose shift data) and EAR data (i.e., AUC data) from an LAR 
study design is therefore difficult to interpret. 
 
 62
  Direct H1 and CysLT1 receptor antagonism at the level of the airway smooth 
muscle is an obvious potential mechanism for preventing the bronchoconstriction associated with 
the LAR by blocking the action of mediators (i.e., histamine and the cysteinyl leukotrienes) 
released by recruited inflammatory cells (e.g., eosinophils and basophils).   However, the single 
dose design, pharmacokinetic and pharmacodynamic (PK/PD) properties of the drugs and the 
response to combination therapy challenge this rationale.   To elaborate, the dose of each 
treatment is taken 2 hours prior to the start of the allergen challenge, the duration of which is, on 
average, approximately one hour and the FEV1 is measured at various time points over the next 7 
hours.  Additional measurements of FeNO, airway hyperresponsiveness to methacholine and 
sputum eosinophils are also captured up to 24 hours after the challenge.  Montelukast has a half 
life of 2.7 to 5.5 hours.  Therefore, 50 – 75% of the drug is potentially cleared at the time the 7 
hour measurements are taken yet we still observe significant inhibition of the FEV1 with 
montelukast at this time point (Figure 5.3).  Conversely, the half life of desloratadine is 27 hours 
yet, the effect of desloratadine is no different than placebo at 7 hours when assessed as changes 
in FEV1. One possible explanation is that the relative potency of cysteinyl leukotriene induced 
bronchoconstriction is 1000 fold more potent than that of histamine.  If cysLT1 receptors are 
unopposed, as would be the case with desloratadine monotherapy, the protective effect of 
desloratadine may be undetectable.  However, this rationale cannot explain the inhibitory effects 
observed on the LAR AUC or the allergen induces changes in airway responsiveness to 
methacholine, exhaled nitric oxide levels or sputum eosinophil counts which suggests a more 
complex mechanism of action than that of direct H1 and cysLT1 receptor antagonism.   
 
  Both histamine [Thurmond et al., 2008] and the leukotrienes [Busse and Kraft, 
2005; Woszczek et al., 2008; Woszczek et al., 2008] play a role in leukocyte recruitment and we 
indeed provide evidence of a decrease in sputum eosinophils with desloratadine and the 
combination at 7 hours and montelukast and the combination at 24 hours.  A trend for increased 
efficacy with combination therapy is apparent but the difference between the two monotherapies 
and the combination therapy at the two time points is not significant.  Earlier investigations have 
shown leukotriene antagonists to significantly reduce eosinophil trafficking to the airway 
following allergen inhalation.  Leigh et al., [2002] documented less of an increase in sputum 
eosinophils following 10 days of 10 mg/day montelukast at both 7 hours and 24 hours post 
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allergen challenge and Parameswaran et al., [2004] also documented a decrease in sputum 
eosinophils at 7 hours and 24 hours post allergen inhalation following two weeks of pranlukast.  
There is however at least one report documenting no change in allergen-induced sputum 
eosinophilia at 24 hours post allergen challenge following 3 doses of montelukast administered 
at 36 and 12 hours prior to challenge and 12 hours after challenge [Diamant et al., 1999].   The 
discrepancies in these data are difficult to explain   We do observe a trend in our data towards an 
inhibition of sputum eosinophils at 7 hours post allergen challenge with montelukast and one 
could suggest that the single dose design was the limiting factor since two other studies have 
shown a significant reduction in 7 hour sputum eosinophils following longer LTRA dosing 
regimens (10 days and 14 days).  However, the single dose explanation for lack of efficacy at 7 
hours is difficult to accept given the observed significant reduction in sputum eosinophils at 24 
hours.  Our study, taken together with the Leigh et al., [2002], Parameswaran et al. ,[2004], and 
Diamant et al., [1999] studies appear to offer inconclusive findings on the effects of LTRA’s and 
sputum eosinophil counts following allergen challenge which warrant further investigation. 
 
  To our knowledge, this is the first report of the effect of desloratadine on sputum 
eosinophil counts following allergen inhalation challenge.  We report that a single 5 mg dose of 
desloratadine decreases the number of sputum eosinophils at 7 hours post inhalation by 
approximately 50 %.  The effect of desloratadine is noted to trend to an even greater degree 
when combined with montelukast, which is similarly observed at the 24 hours time point in that 
the significant inhibition of eosinophil recruitment by montelukast is trending even higher with 
the addition of desloratadine.  The mechanism by which these agents, both alone and in 
combination, are suppressing eosinophil recruitment in vivo requires further investigation.   
 
  Increased responsiveness to direct acting stimuli (e.g., methacholine) is another 
hallmark of the late airway response to allergen.    The increase in airway responsiveness 
following placebo (i.e., decrease in methacholine PC20) 24 hours post allergen inhalation was 
unaffected by all active treatments.  This is the first report of the effects of desloratadine on 
allergen induced changes in methacholine PC20 and our results are consistent with previous 
investigations which have shown no change in airway responsiveness following allergen 
exposure and pre-treatment with an H1 blocker [Twentyman et al., 1993; Bentley et al., 1996]. 
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The literature surrounding the effect of leukotriene antagonists on allergen induced changes in 
methacholine responsiveness is controversial.  Palmqvist et al., [2005] documented no change in 
methacholine PC20 following 8 days of montelukast monotherapy, conversely however, 10 
mg/day of montelukast for 10 days did decrease the response as shown by Leigh et al., [2002] 
and 300 mg/bid of pranlukast for 2 weeks also prevented the allergen induced increase in airway 
responsiveness to methacholine as shown by Parameswaran et al., [2004]. Taylor and 
O’Shaughnessy, [1991] have also documented an inhibitory effect on the allergen induced 
increase in airway responsiveness to histamine following single dose administration of a 
leukotriene receptor antagonist (ICI204.219; developed as zafirlukast) given 2 hours prior to 
allergen challenge.  While our investigation is similar to that of Taylor and O’Shaugnessy (i.e., 
single dose administered 2 hours prior to allergen challenge) direct comparison is again difficult 
due to the choice of direct acting agent (i.e., histamine versus methacholine) and the differences 
in the time points that the measurements were made.  Most allergen challenge studies assess this 
parameter using 24 hour pre and post allergen challenge data. In the Taylor and O’Shaughnessy 
study, measurements were taken approximately 3 hours pre and 7 hours post allergen challenge 
and the data at these time points is difficult to interpret as being the response to methacholine or 
as being an apparent response to methacholine due to the changes in airway caliber evoked by 
the LAR itself. 
 
  The relationship between airway inflammation and airway hyperresponsiveness 
following allergen exposure remains unclear.  Our data support a relationship between these 
parameters in that a reduction in sputum eosinophils parallels a trend towards a significant 
decrease in airway hyperresponsiveness with montelukast and the combination at the 24 hour 
time point.  Additionally, at this time point, desloratadine did not affect eosinophil recruitment 
and there was no change in the increase in airway responsiveness to direct stimuli.  Although, as 
mentioned, interpretation of the response to methacholine would have been difficult, it would 
have been interesting to have measured the methacholine PC20 at the 7 hour time point. 
 
  With the exception of montelukast, which significantly suppressed the allergen 
induced increase in FeNO at the 24 hour measurement, there were no treatment effects on this 
parameter.  The amount of exhaled nitric oxide has been shown to increase after allergen 
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exposure [Duong et al., 2007] and has been reported to correlate with the degree of eosinophilic 
inflammation. [Jatakanon et al., 1998].  Even though desloratadine reduced eosinophil influx, H1 
receptor antagonism did not affect FeNO at 7 hours suggesting the source of FeNO at this time 
point may not be eosinophilic in nature.  Conversely, a reduction in eosinophils following 
montelukast is indeed associated with a reduction in FeNO at 24 hours.  The temporally 
associated differences may be related to the kinetics of eosinophil activation.  It may also be 
worth noting that FeNO is trending higher following antihistamine and this is perhaps reflected 
in the apparent antagonistic effect following combination therapy (i.e., effect of combination on 
FeNO levels is less than the effect of montelukast alone).  Nonetheless, relative to bronchial 
biopsy and bronchial lavage, exhaled nitric oxide is an attractive non-invasive procedure for 
assessing airway inflammation and therapeutic efficacy when incorporated into the allergen 
challenge model.  The results however must be interpreted with caution as the reported lack of 
specificity and selectivity of FeNO measurements may limit the usefulness of the data 
[Pendharkar et al., 2008].  We must also acknowledge that the study may not be appropriately 
powered to detect a significant change in FeNO. 
 
  The biological role of histamine and the leukotrienes in the pathogenesis of 
asthma is an area of great interest.  Many of the cells involved in the inflammatory process and 
the immune response possess histamine and/or leukotriene receptors which may serve as 
potential therapeutic targets for altering these responses.  In addition to leukocyte recruitment, 
histamine may have a role in regulating the phenotype of dendritic cells and T cells, [Akdis and 
Blaser, 2003] direct T cell trafficking [Bryce et al., 2006] and influence cytokine signaling 
[Schneider et al., 2002].  Whether or not any of these potential mechanisms can explain our 
results needs to be investigated. 
 
  The importance of histamine and the leukotrienes in the EAR via airway smooth 
muscle contraction has been well documented.  Our current investigation provides clinical 
evidence that these mediators alone, but to a greater extent in combination, are also important in 
the development and manifestation of the LAR.   The clinical relevance of our data is unknown 
considering the currently available treatments that effectively suppress the LAR which include 
the long acting 2 agonists (short if used following EAR), single dose inhaled 
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glucocorticosteroids, combination therapies such as Symbicort® and Advair®, and anti-IgE.   
Importantly however, there is a subpopulation of individuals with atopic asthma who are treated 
with only infrequent short acting bronchodilators.  Although the relief provided by the use of 
rescue bronchodilators is beneficial, it can be problematic with overuse.  In addition, 
prophylactic prevention of the LAR may be a preferred option over masking the response with 
functional antagonism given the suspected role of inflammation on tissue remodeling.  It is 
therefore these individuals who may benefit from combined desloratadine and montelukast 
therapy when exposure to a triggering allergen is imminent. 
 
  In summary, we provide evidence that concurrent, single dose administration of 
desloratadine and montelukast impressively and significantly blocks both the early and the late 
airway responses to inhaled allergen in individuals with mild atopic asthma.  The mechanisms by 
which the combination exerts this inhibitory effect and the effect of combined therapy on the late 
sequelae requires further investigation. 
 67
Table 5.1:  LAR Study Subject Demographics 
Subject Gender Age  (years) 
Height 
(inches) 
Baseline 
FEV1  
(litres) 
Baseline 
FEV1 % 
Predicted 
Allergen 
** 
Allergen 
Dilution 
*** 
MPC20 
(mg/mL) 
Medications 
1 M 60 66 2.42 74 grass 1:256 0.56 S 
2 F 24 61 3.29 106 hdm (dp) 1:256 2.5 S 
3 M 30 70 3.41 77 cat 1:256 0.34 S 
4 M 25 71 4.25 91 grass 1:64 1.4 S 
5 M 24 73 3.49 71 grass 1:128 1.7 S B 
6 F 47 66 2.47 84 cat 1:128 7.0 S 
7 M 58 71 3.44 90 cat 1:128 1.3 S 
8 F 26 65 3.75 110 hdm (df) 1:64 11.7 S 
9 M 23 72 5.22 107 cat 1:32 5.3 S 
10 F 44 68 3.72 122 cat 1:4 5.6 S F 
Mean 
( SD)  
36.1 
(14.8) 
68.3 
(3.8) 
3.55 
(0.81) 
93.2 
(17.3)  
 
*2.27 
  
Legend:  *geometric mean; ** final concentration of allergen administered; ***methacholine 
PC20; hdm, house dust mite; dp, dermatophagoides pteronyssinus; df, dermatophagoides farinae; 
S, salbutamol – prn; B, budesonide – 400mcg/day; F, flonase – 2 squirts/nare/day 
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Table 5.2:  Dose and effects of H1 blockers and LTRA’s on the airway response to allergen 
Author Treatment Daily Dose Duration 
AUC EAR / max 
↓ FEV1 
(% inhibition) 
AUC LAR / max 
↓ FEV1 
(% inhibition) 
loratadine 20 mg 25/31 40/32 
zafirlukast 160 mg 62/62 55/36 Roquet et al., 
[1997] 
 loratadine + 
zafirlukast 
20 mg/160 mg 
 
1 week 
75/74 74/48 
azelastine 8.0 mg NR/46 NR/43 
montelukast 10 mg NR/76 NR/59 
Richter et al., 
[2008] azelastine 
+ 
montelukast 
8.0 mg/10 mg 
1 week 
NR/89 NR/78 
desloratadine 5 mg 32/14 43/19 
montelukast 10 mg 72/54 71/63 
Davis et al., 
[current study] desloratadine 
+ 
montelukast 
5 mg/10 mg 
single dose 
2 hours prior to 
allergen 
challenge 100/73 100/88 
NR, not reported
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p = 0.066
n = 10
ANOVA p < 0.001
 
Figure 5.2 Treatment effects on the LAR AUC.  
 Treatment dependent inhibition of the LAR expressed as mean area under the 
curve 3 to 7 hours post allergen inhalation.  All treatments significantly decreased the LAR.  The 
difference between desloratadine and montelukast was not significant.  The combination of 
desloratadine and montelukast was superior to that of montelukast.   
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Placebo Desloratadine Montelukast Desloratadine
Mean AUC
EAR
0
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30
40
50
+ Montelukast
p = 0.04
p = 0.012
p = 0.052
n = 10
ANOVA p < 0.001
 
Figure 5.3 Treatment effects on the EAR AUC.  
 Treatment dependent inhibition of the EAR expressed as mean area under the 
curve 0 to 3 hours post allergen inhalation. Desloratadine, montelukast and the combination all 
significantly decreased ( p < 0.05) the EAR AUC.  The difference between combination therapy 
and montelukast therapy is not significant (p = 0.052). 
  . 
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Figure 5.4 Treatment effects on the Mean % Fall in FEV1. 
Changes in FEV1 over the 7 hours post allergen inhalation expressed as the mean 
percent fall in FEV1 for each treatment arm.  Combination therapy and montelukast monotherapy 
were superior to that of desloratadine monotherapy and placebo.  Combination was not 
significantly different from montelukast monotherapy and desloratadine monotherapy was not 
significantly different than placebo.  C, combination of montelukast and desloratadine; M, 
montelukast monotherapy; D, desloratadine monotherapy; P, placebo.   
n = 10 
ANOVA p < 0.0001 
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Figure 5.5 Treatment effects on the allergen induced increase in airway hyperresponsiveness 
to methacholine. 
 Airway responsiveness to methacholine expressed as the dose shift from 24 hours 
prior to allergen challenge to 24 hours after allergen challenge.   Active treatments did not have 
an effect on the allergen induced increase in airway responsiveness.  A trend is apparent with 
montelukast and combination therapy. 
 
Treatment
Placebo Desloratadine Montelukast Desloratadine
Methacholine
Dose Shift
(doubling doses)
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
+ Montelukast
 
n = 10 
ANOVA p = 0.092 
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Figure 5.6 Treatment effects on the allergen induced increase in exhaled nitric oxide. 
Mean absolute change in the fraction of exhaled nitric oxide levels 24 hours after 
allergen inhalation.  Montelukast was the only treatment to significantly suppress the allergen 
induced increase in exhaled nitric oxide (*p<0.05).  
 
 
 
 
 
n = 10 
ANOVA p = 0.033 
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Figure 5.7  Treatment effects on allergen induced sputum eosinophilia at 7 hours. 
Percent increase in sputum eosinophils 7 hours post allergen inhalation.  
Pre-treatment with desloratadine and the combination of desloratadine and montelukast 
significantly decreased eosinophil recruitment at this time point (*p<0.05). P, placebo; D, 
desloratadine; M, montelukast; D+M, desloratadine in combination with montelukast. 
Treatment
P D M D + M
 sputum
EOS(7h) (%)
0
5
10
15
20
25
30
*
*
*
n = 10 
ANOVA p = 0.006 
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Figure 5.8 Treatment effects on allergen induced sputum eosinophilia at 24 hours. 
  Percent increase in sputum eosinophils 24 hours post allergen inhalation.  Pre-
treatment with montelukast and the combination of desloratadine and montelukast significantly 
decreased eosinophil recruitment at this time point (*p<0.05). P, placebo; D, desloratadine; M, 
montelukast; D+M, desloratadine in combination with montelukast. 
n = 10 
ANOVA p = 0.036 
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6.0 OVERALL GENERAL DISCUSSION 
 
 We have shown that a single dose of the combination of a selective H1 antagonist with a 
selective CysLT1 antagonist provides superior efficacy towards inhibiting the airway responses 
to inhaled allergen in individuals with mild atopic asthma.  Our initial study showed that two 
clinically relevant doses of desloratadine in combination with two clinically relevant doses of 
montelukast, administered 24 hours apart and two hours prior to exposure, synergistically 
inhibited the EAR to inhaled allergen in individuals with mild atopic asthma.  Montelukast alone 
was superior to desloratadine which failed to suppress the response.  These data, together with 
emerging data on the anti-inflammatory effects of both agents, led to the hypothesis that this 
particular combination would be effective in suppressing the LAR and related sequelae.  In that 
regard, we also showed superior protection against the LAR AUC with the combination versus 
either drug alone. Additionally, the combination suppressed the allergen induced increase in 
eosinophil recruitment at both 7 hours and 24 hours; trended toward suppressing the allergen 
induced increase in airway hyperresponsiveness to direct stimuli; but failed to alter the allergen 
induced increase in exhaled nitric oxide.  
 
At the time our LAR investigation began, the Roquet et al., [1997] study was the only 
clinical evidence of the effect of these types of drugs, administered in combination, on the 
airway response to allergen in atopic asthma.  The inhibitory effect of combining a histamine H1 
receptor antagonist with a leukotriene receptor antagonist on the airway response to inhaled 
allergen has now been confirmed by Richter et al., [2008] and ourselves.  Taken together, these 
three investigations provide a unique opportunity for post hoc observations and discussion 
regarding the class effects of these agents on the LAR to allergen in mild atopic asthma using 
single, multiple and high dose administration. 
 
The FEV1 data of the three LAR investigations is summarized in Table 5.2.  The data is 
also graphically represented in Figure 6.1.  Note that a single dose of montelukast and 
desloratadine, alone or in combination, appears to exert approximately equal effects on the EAR 
and LAR for a given treatment, although the effect on the LAR is always greater than that on the 
EAR.  This pattern seems to be lost when much higher doses are given over a longer time period 
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(i.e., Roquet study) such that the magnitude of the effect on the LAR is more than 40 % less than 
that on the EAR. 
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Figure 6.1:  Comparison of different doses of antihistamine and LTRA administered as 
monotherapy or as combination therapy on the maximal fall in FEV1 following allergen 
inhalation challenge in individuals with mild atopic asthma.  
 
  COMBO is either zafirlukast and loratadine, montelukast and azelastine or 
montelukast and desloratadine corresponding to the dosing regimes of high dose 7 days, clinical 
dose 7 days and single dose pre challenge respectively.  Note that the longer duration and higher 
dose regimens show a loss of efficacy on the LAR with combo and LTRA treatments compared 
to the single dose regimen.  Circles represent antihistamine; squares represent LTRA and 
triangles represent combination therapies.  
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following combined therapy and LTRA monotherapy.  When these types of drugs are provided 
at clinically recommended doses, the effect on the LAR with combination and LTRA 
monotherapy is again less than that observed for the EAR but the decrease is not as great (~ 22 
%).   Loss of therapeutic efficacy is often due to the development of tolerance through 
downregulation of receptors, a general pharmacological principal commonly seen with excessive 
agonist activity where prolonged signaling results in a counteractive response by the body to turn 
the signal off by decreasing the number of available receptors.  Conversely, a prolonged 
inhibition of the signal by an antagonist may lead to receptor upregulation and an apparent loss 
of therapeutic efficacy.  There is however, no existing evidence to suggest that montelukast or 
LTRA’s in general are subject to the development of tolerance. We also observe that this 
apparent loss of effect does not appear to occur with histamine H1 receptor antagonist 
monotherapy.  Across all three studies, the inhibitory effect of the antihistamine arm on the EAR 
and LAR was consistent and approximately equal.  The reason that this may be occurring with 
LTRA and not histamine H1 receptor antagonists might be explained by the dual active/inactive 
conformations of the histamine H1 receptor such that the endogenous state of being in one form 
or the other does not necessitate a counteractive response.  All H1 receptor antagonists are 
recognized as inverse agonists.  As such, these agents produce the reverse effect of histamine, 
essentially decreasing the constitutive activity in the absence of histamine.  In other words, if the 
H1 receptor exists in two forms, active and inactive, such that the agonist histamine stabilizes the 
receptor in the active form producing a response, the inverse agonist stabilizes the receptor in the 
inactive form producing an apparent response in equal magnitude to that of the agonist but in the 
opposite direction due to inhibition of the constitutive activity.  In the presence of both agonist 
and inverse agonist the system remains “balanced” (Figure 6.2).  Theoretically, the 
administration of antihistamine could therefore result in bronchodilation.  The lack of an 
improvement in baseline FEV1 values in the three studies is likely explained by the sample 
population and is analogous to the lack of bronchodilator response to inhaled beta agonist (i.e., 
test of reversibility) in this population.  That is, in a sample of individuals with mild atopic 
asthma who are asymptomatic and have near normal baseline lung function underlying 
bronchoconstriction is absent and bronchodilator treatments do not exhibit reversibility.  The 
issue of documenting reversibility in this subject population has been and continues to be a 
challenge in meeting the inclusion criteria of some clinical trial protocols. 
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Figure 6.2:   Inhibition of histamine signaling in the presence of desloratadine.  The active 
receptor favors histamine whereas the inactive receptor favors desloratadine.  In the absence of 
desloratadine the system responds to histamine signaling leading to airway smooth muscle 
contraction and desloratadine would theoretically produce airway smooth muscle relaxation in 
the absence of histamine.  When both are present the system remains in balance.
H1 H1 
(active) (inactive)
+ histamine
+ desloratadine
+ histamine + desloratadine
bronchoconstriction 
bronchodilation 
When both agonist and inverse agonist are present the 
system is balanced and no response is observed 
In the absence of agonist and inverse agonist the 
system is balanced 
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 This post hoc observation suggests that combining an LTRA with a histamine H1 receptor 
antagonist will significantly decrease the airway response to allergen but the inhibitory effect on 
the more clinically relevant response, the LAR, is dampened by multiple doses and is lost to an 
even greater extent with multiple high dose administration that appears to be specifically related 
to a loss of effect of the LTRA.  One might question the clinical relevance of this given that the 
responses of the individual LTRA treatments and the combination treatments in the Roquet et al., 
[1997] and Richter et al., [2008] studies are still significant when compared to placebo.  What is 
unknown at this point however is whether the apparent loss of effect amplifies with treatment 
regimes extending beyond 7 days.  Other possible explanations of the apparent loss of efficacy 
on the LAR in the two earlier studies include differences in magnitude of the LAR, that is, if the 
overall LAR responses were greater than in our study, the effect of the LTRA may appear less, 
and the use of different LTRA’s and antihistamines. 
 
 Post hoc observations aside, the results of our LAR investigation and those of Roquet et 
al., [1997] and Richter et al., [2008] reproducibly show that the combination of an antihistamine 
and a leukotriene receptor antagonist clinically and significantly suppress the airflow obstruction 
that develops following allergen inhalation better than either agent alone.  Our results add to the 
literature by documenting significant inhibition of the LAR after a single dose of each agent as 
monotherapy and taken concomitantly two hours prior to allergen exposure.  Impressively, the 
effect on the LAR AUC and EAR AUC with combination is complete inhibition.  Additionally, 
our first investigation showed that the combination exhibits a synergistic effect on shifting the 
allergen PC20 whereas previous investigations had shown no difference between the combination 
of an antihistamine and an LTRA with that of an LTRA alone. 
 
 Taken together, the investigations of combined LTRA and antihistamine provide clinical 
evidence to suggest that there may indeed be a role for this type of treatment in individuals with 
atopic asthma.  A single dose of a combination tablet would benefit individuals who do not 
require regular controller medication, yet know that exposure to a triggering agent is imminent.   
Importantly, this excludes individuals whose asthma is triggered by agents that cannot be 
avoided such as seasonal pollens and house dust mite (i.e., seasonal or perennial asthma).  For 
these individuals, we know from the Roquet et al., [1997] and Richter et al., [2008] data that 
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there is also benefit with daily use.   It seems therefore that a single tablet combining an 
antihistamine and an LTRA would be beneficial.  Interestingly, in 2007, a New Drug Application 
was made to the FDA by Schering-Plough and Merck Frosst for a combined montelukast and 
loratadine tablet for the treatment of allergic rhinitis.  The application however was denied.  
[Schering-Plough website].  Perhaps the recent favorable evidence in suppressing allergen 
induced asthma will spark additional research and a future application to the FDA or the 
Canadian Therapeutic Products Directorate (TPD) for the treatment of atopic asthma, allergic 
rhinitis and the co-morbid condition of allergic rhinitis plus atopic asthma.  
 
 Insight on the mechanism of action of the combination of desloratadine and montelukast 
may be appreciated through pharmacological profiling or comparative pharmacology of agents 
that are more widely understood (Table 6.1).  For example, the degree of inhibition on the EAR 
afforded by the combined action of H1 and cysLT1 airway smooth muscle receptor antagonism 
that was used in our research, has been similarly documented with  agonist, anti-IgE and 
sodium cromoglycate which is superior to that seen with anti-muscarinics, and single or stable 
dose inhaled glucocorticosteroids.  We know that  agonists are functional antagonists of airway 
smooth muscle contraction. We know that anti-IgE binds free IgE preventing the formation of 
the allergen•IgE•FcRI complex and subsequent mast cell degranulation and we know that 
sodium cromoglycate, at least in part, stabilizes mast cells.  Collectively, these different 
mechanisms reinforce our current understanding of the mechanism of the EAR as being acute 
bronchoconstriction resulting from mast cell mediator release. Less studied, and less understood, 
however, is the mechanism of recovery from the EAR.  Early investigations, reviewed in Chapter 
3, have implicated histamine and the leukotrienes as being responsible for the initial and 
prolonged phases, respectively, of ex vivo bronchial contractility.  Consistent with this, we do 
observe an earlier maximal response and a more complete recovery with less time taken to 
achieve complete recovery with the combination therapy (Figure 5.4).  Questions that are worth 
asking are whether the inhibitory effect is occurring through parallel or tandem actions of two 
independent pathways or through the combined action of two mediators on a single pathway or 
through non H1 cysLT1 activation.  We know that both H1 and cysLT1 receptors are coupled to 
the same G protein, specifically, Gq/11 and this may play a role in the suppression of the response 
via a “taxing” of a common second messenger signaling pathway.  Additionally, if H1 and cys  
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Table 6.1 Comparative Pharmacology of EAR Inhibition (Rank Order) 
Drug 
% inhibition 
(max % ∆ 
FEV1) 
Dose shift Fold ∆ Reference 

2 agonist 
(salbutamol) 
 
n/a 3.9 ~ 15 
Cockcroft et 
al, 
1993 
 
H1 Blocker /LTRA 
(desloratadine/montelukast) 
 
n/a 3.0 8 Davis et al, 2009 
 
Anti-IgE 
(omalizumab) 
 
n/a 2.7 6.5 Boulet et al, 1997 
 
SCG 
(sodium cromoglycate) 
 
~ 75 2.0 4 Pepys et al, 1974 
 
LTRA 
(zafirlukast) 
 
50-75 ~ 1.5 3 Roquet et al, 1997 
Regular ICS 
(beclomethasone 
dipropionate) 
~ 50 1.3-1.5 2.3-3.0 
Cockcroft et 
al, 1995 
Swystun et al, 
1998 
 
H1 Blocker 
(azelastine) 
 
≤ 46 ~ 0.6 ~ 1.6 Richter et al, 2008 
Theophylline 25-50 ~ 0.7 ~ 1.7 Hendeles et al, 1995 
 
Muscarinic antagonist 
(ipratropium bromide) 
 
~ 25 0.5 ~ 1.5 
Cockcroft et 
al, 
1978 
n/a = not applicable; these are EAR investigations where an actual dose shift is measured 
LTRA = leukotriene receptor antagonist; IgE = immunoglobulin E; SCG = sodium cromoglycate 
ICS = inhaled glucocorticosteroids 
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 LT1 receptor antagonism leads to a localized increase in the amount of histamine and 
leukotrienes, these mediators and their metabolic products (e.g., N-methylhistamine) are free to 
activate the nearby unopposed H2 - H4 and cysLT2 receptors.  This could potentially lead to, for 
example, a decrease in the amount of histamine and/or leukotrienes released from mast cells 
through a process of negative feedback regulation via H2 and/or cysLT2 receptors.   
Bronchodilation via H2 receptors is another possibility as is the initiation of physiological 
responses via H4 and cysLT2 receptor activation which, with respect to asthma, we know 
relatively little about. 
 
 The mechanism of action of how these agents, both as monotherapy and more 
importantly as combined therapy, are exerting these positive clinical actions on the LAR 
warrants further investigation.   While it is attractive to suggest that the airway constriction is 
mediated through the action of histamine and the leukotrienes released from recruited 
eosinophils and basophils there are mounting data, most of which pertain to eosinophils, that 
document inhibition of  leukocyte recruitment without affecting the LAR.   The role of the 
basophil has not been studied in detail even though this cell is a major source of histamine and a 
temporal relationship between the LAR and basophil recruitment has been recently shown 
[Gauvreau et al, 2000].  Undoubtedly there are other cellular sources of histamine and the 
leukotrienes and cells with high levels of histidine decarboxylase (e.g., dendritic cells and T 
cells) have been shown to produce histamine de novo the biological role of which is not clear.  
The in vitro and animal data reviewed in Chapter 2 suggest both desloratadine and montelukast 
may be exerting anti-inflammatory actions that include decreases in IL-4, IL-5 and IL-13.  [Wu 
et al, 2004; Maeba et al, 2005; Wu et al, 2006 ; Roumestan et al, 2008].  Based on our current 
understanding that the LAR is a Th2 driven response involving leukocyte recruitment, 
orchestrated primarily by IL-4, IL-5 and IL-13, these earlier mechanistic data offer a possible in 
vivo mechanism.  However, there is evidence from investigations of agents which specifically 
target these cytokines or their receptors that have produced equivocal results on inhibiting the 
LAR in spite of decreasing inflammatory cell recruitment [Leckie et al, 2000; Wenzel et al, 
2007].  Recent preclinical data support a role for histamine and the leukotrienes on dendritic cell 
and T cell differentiation and function.  This is an attractive potential mechanism that requires 
further investigation.  Theoretically, blocking or manipulating the immune and inflammatory 
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responses upstream of the plethora of mediators and cell signals that occur subsequent to T cell 
activation may be more effective than trying to target various individual components of a 
response that amplifies as it proceeds.   
 
 In closing, the prevalence of asthma is increasing, and allergies are common triggers of 
symptoms and exacerbations.  Treatment options have undergone few changes of late and 
investigations of new treatments seem to be focusing on biologics that will be too costly and, for 
the most part, unnecessary, in the majority of patients.   There are two classes of drugs, namely 
antihistamines, second generation H1 antihistamines in particular, and leukotriene receptor 
antagonists, which are currently approved for the treatment of allergic rhinitis and asthma.  Our 
results, together with that of Roquet et al., [1997] and Richter et al., [2008] have provided 
clinical evidence of superior inhibition of airway responses to allergen in mild atopic asthma 
when used concomitantly.  Whether or not specific combinations are more efficacious than 
others is yet to be determined but desloratadine in combination with montelukast might be 
favored based not only on efficacy but on dosing convenience and superior safety profiles in 
both adults and children.   
 
7.0 FUTURE RESEARCH 
  
 We will follow up our early and late response studies using sputum supernatant and 
peripheral blood serum samples obtained during the LAR investigation to examine changes in 
these tissues that may help explain our results. 
 
We hope that other researchers in the field will also be inspired by these data to undertake 
mechanistic investigations that will collectively delineate how the combination provides superior 
efficacy and advance our knowledge surrounding the role of histamine and the leukotrienes not 
only in asthma pathophysiology but other inflammatory and immune disorders as well.   
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9.2 APPENDIX B:  Ethics Documentation for the Early Asthmatic Response Study 
 
9.2.1 Researcher’s Summary 
 
 
 
 
 
UNIVERSITY OF SASKATCHEWAN 
RESEARCH ETHICS BOARD 
(Biomedical)\ 
http://wwwusask.ca/research/ethics.shtml 
 
   ORS USE ONLY 
 
      Date received:  ___________________ 
 
File Number:  _____________________ 
 
RESEARCHER’S SUMMARY 
 
PROJECT TITLE: 
 
Effects of combined leukotriene (montelukast), histamine (desloratadine) antagonism on the 
early response to inhaled allergen. 
 
PRINCIPAL INVESTIGATOR:   Dr. D.W. Cockcroft  
 
DEPARTMENT:  Medicine, Division of Respiratory Medicine 
 
SUB-INVESTIGATOR(S):  __________________________________________  
 
DEPARTMENT: _________________________________________ 
   
RESEARCH WILL BE CONDUCTED AT:    Room 346, Ellis Hall 
______________________________________________________________________________ 
 
1. Hypothesis  (State briefly the nature and purpose of the research proposal, and the 
proposition the research is seeking to uphold. What potentially useful knowledge or clarification 
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about therapeutic options will be advanced to justify the participation of human subjects in this 
research project?): 
 
 Leukotriene receptor antagonism in combination with histamine receptor antagonism will 
provide greater protection against allergen induced bronchoconstriction than either drug 
administered alone. 
 
2. Academic Validity (Provide evidence that the scientific reasoning and design of the 
project are sufficiently sound to meet the objectives of this project. Provide your own comments 
and those resulting from peer review.  Indicate if any committee or other body has assessed the 
project’s scientific validity):   
 
 Mediators released during mast cell degranulation include the leukotrienes and histamine.  
Allergen exposure triggers mast cell degranulation in atopic asthmatics and is responsible for the 
early asthmatic response (EAR).  Receptor antagonists that selectively block the binding of these 
endogenous autocoids should prevent or at least decrease the EAR.  The leukotriene receptor 
antagonist (LTRA) montelukast is effective in the treatment of asthma (non-atopic) and the 
histamine antagonist (HA) desloratadine is effective in the treatment of seasonal allergic rhinitis 
and chronic idiopathic urticaria.  The current indications of these medications, speculation of 
possible anti-inflammatory/immunomodulatory actions and the multi-mediated mechanism of the 
EAR suggest that combined therapy would be beneficial in preventing the EAR. 
 
3. Funding (indicate the source of funds supporting the research.  If externally funded, state 
whether the grant or contract is still in application, or has already been awarded): 
 
 Supply of study medication and placebo has been requested from Merck Frosst 
(montelukast and matching placebo) and Schering Plough (desloratadine and matching placebo).  
No formal funding is expected. 
 
4. Disclosure of Potential Conflicts of Interest (indicate any motivation or incentives for 
conducting this study that arise external to the objectives of the study, e.g.,, will the investigator 
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or institution be paid to conduct this research project? Note:  The consent form should also 
include an introductory disclosure of potential conflict of interest statement indicating that this is 
a medical research study for which the study doctor is being paid to conduct): 
 
 N/A 
 
5. Subjects (target population e.g.,, age, gender, medical condition, target enrollment at this 
site, proposed strategies that will be used to recruit to this study): 
 
 Twelve well controlled atopic asthmatics 18 years of age or older.  Recruitment will 
likely be completed with individuals who have previously participated in research and have 
agreed to being contacted for future projects.  Poster advertisement around campus as well as the 
university hospital may be undertaken.  An ad may also be placed in the university newspaper. 
 
6. Procedures (clearly identify treatment allocation design, and describe the medical and 
other procedures to be followed in obtaining research data):   
 
 The study design will be randomized, four way, placebo controlled, double blind, double 
dummy.  Two doses of each antagonist (10mg montelukast and 5mg desloratadine) will be 
administered 24 hours apart.  The second dose will be given two hours prior to each allergen 
challenge and the first dose will be given 26 hours prior to each allergen challenge.  
Investigations will include baseline spirometry, methacholine challenge test, and skin prick 
testing for eligibility.  Continuing subjects will undergo a baseline allergen challenge prior to 
randomization.  Data collection (allergen PC20) measurements will be conducted on four 
occasions with a minimum of seven days between challenges. 
 
7. Time Period  (indicate the dates when the research project is expected to begin and to be 
completed.  A final status report must be filed with the Office of Research Services once data 
collection from the last subject is complete. ORS should be notified once the study site is 
closed.): 
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 January 2004 – January 2005. 
 
8. Consent Form (include a copy of the study information / consent form that will be used, 
or give reasons if one is not being used): 
 
 Attached. 
 
9. By signing below, the Principal Investigator is assuring the Biomedical Research Ethics 
Board that the Department Head (or corresponding senior administrator) has received a copy of 
this Researchers' Summary Form.  (NOTE:  This policy will function in lieu of the previous 
policy that required countersigning of this Researchers' Summary Form by the Department 
Head). 
  
 Dr. Donald Cockcroft    966-8346 
 Principal Investigator    Phone 
 
 966-8694     cockcroft@sask.usask.ca 
 Fax      E-mail 
 
10. Contact Person and Mailing Address for Correspondence:  
 
 Beth Davis c/o Dr. Cockcroft, Division of Respiratory Medicine, 5th Floor Ellis Hall, 
 103 Hospital Drive, Saskatoon, SK S7N 0W8.  Phone: 966-8290. E-mail: 
 davisb@sask.usask.ca 
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9.2.2 Information Sheet and Consent Form 
 
 
INFORMATION SHEET AND 
CONSENT FORM 
Title: Effect of combined leukotriene (montelukast), histamine (desloratadine) antagonism 
on the early response to inhaled allergen 
Investigator:  Dr. D.W. Cockcroft 
Department of Medicine, Division of Respiratory Medicine 
University of Saskatchewan 
5th Floor Ellis Hall, 103 Hospital Drive 
Saskatoon, Saskatchewan S7N 0W8 
306-966-8346 
 
 
INTRODUCTION 
 
You are being invited to participate in a research project because you have allergies that trigger 
your asthma.  Currently available asthma (montelukast) and allergy (desloratadine) medications 
and their combined effect on people who have allergies that trigger their asthma will be 
investigated. 
 
VOLUNTARY PARTICIPATION 
 
Your participation is entirely voluntary and it is up to you to decide whether or not you want to 
take part in this project.  Before you decide, it is important for you to understand what the 
research involves.  This document will tell you about the study, why the research is being done, 
what will happen to you during the study and the possible benefits, risks and discomforts. 
If you wish to participate, you will be asked to sign this form.  If you decide to take part in this 
study you may still withdraw at any time and without giving any reason. 
If you decide not to participate, you do not have to provide any reason for your decision and you 
will not lose any medical care to which you are entitled or are presently receiving. 
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Please take time to read the following information carefully and to discuss it with your family, 
friends, and/or doctor before you decide. 
 
PURPOSE 
 
Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current 
uses.  Part of what happens when your allergies trigger your asthma should be prevented by 
either of these drugs.  This project is being conducted to determine if these drugs are effective, 
either alone or in combination, on controlling asthma that is triggered by allergies. 
 
PROCEDURES 
 
The duration of the study is approximately 6 weeks and can be divided into two phases, a 
screening phase (testing to determine if you qualify) and a treatment phase (collection of the data 
to be analyzed).  You will be required to attend the lab on at least 7 occasions during the course 
of the study.  The duration of each visit will vary.  Screening procedures will occur over three 
days.  The first day will require about one hour of your time.  The second and third days will 
require two to three hours.  The treatment phase visits could last up to four hours and there are 
four visits.  If you decide to participate in this research project, you will be required to complete 
the following testing: 
 
A.  Breathing Tests 
  
Breathing tests will be conducted at all visits.  You will be required to blow into a machine 
which you hold in your hand.  The machine has a mouthpiece attached to it which you will place 
in your mouth and will inhale and exhale through.  You will also wear noseclips.  The air that 
goes through the machine is measured by a software program that displays the results on a 
computer screen. 
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B.  Skin Prick Tests 
 
The skin prick test will be conducted once.  This will involve small droplets of common 
allergens (animals, pollens, etc.) being placed on your forearm.  A small scratch within the 
droplet will be performed which will determine if you have an allergy to a particular allergen.  If 
so, a small bump similar to a mosquito bite will appear and will likely be red and itchy. 
 
C.  Methacholine Inhalation Test 
 
The methacholine inhalation test will be conducted once.  This will involve breathing maneuvers 
as described above.  In addition, you will be required to inhale a substance called methacholine 
which may cause your airway to constrict.  You will be inhaling increasing concentrations of 
methacholine by placing a mask over your nose and mouth. The mask is attached to an aerosol 
generating piece of equipment which functions to provide an inhalable solution of the substance.  
You will inhale the substance by breathing normally for two minutes.  Any constriction that may 
result will be monitored by the breathing maneuvers.  When and if a certain value is reached 
(20% decrease), the test will be stopped and any constriction that has occurred will be reversed 
with a bronchodilator (Ventolin®) or you may choose to let the constriction reverse on its own.  
Either way, your breathing must return to within 10% of the value it was when the test began 
before you may leave the lab. You may also stop the test at any time for any reason. 
 
D. Skin test endpoint 
 
The skin test endpoint is identical to the skin prick test except that one allergen of various 
concentrations is placed on the forearm, scratched and monitored for response.  This test will be 
done once. 
 
E.  Allergen Challenge Test 
 
The allergen challenge test will be performed on five occasions.  Each allergen challenge will be 
separated by at least 7 days.  Again, breathing maneuvers will be performed as described above 
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and will be used to monitor any constriction that occurs.  You will be required to inhale 
increasing concentrations of one of the allergens identified in the skin prick test.  The inhalation 
is done through a mouthpiece with a noseclip on for two minutes of normal breathing.  When the 
constriction in your airways reaches a certain value (15%) the test will be stopped.  
Bronchodilator (Ventolin®) and inhaled steroid (Flovent®) will be administered to reverse the 
immediate constriction and to prevent subsequent inflammation and constriction. 
 
F.  Administration of the drugs, montelukast and desloratadine 
 
This is a placebo controlled study.  Placebo controlled means there are tablets that look like the 
active drug but do not contain any active drug.  There are four separate treatments and you will 
be required to complete all four.  The order in which you complete each treatment will be 
random.  Neither you nor the study personnel will know what treatment you are taking.  This 
information can however be obtained if necessary. 
 
Both montelukast and desloratadine are currently available by prescription under the trade names 
Singulair® and Aerius® (CAN)/Clarinex® (US) respectively.  The recommended dosage is 
10mg a day for Singulair® and 5mg a day for Aerius®.  This will be the dose you will be 
required to take two times before each allergen challenge.  The first dose will be taken 26 hours 
before the challenge and the second dose will be taken 2 hours before each allergen challenge. 
 
RISKS AND DISCOMFORTS 
 
A.  Methacholine and allergen inhalation tests 
 
The inhalation challenges may cause bronchoconstriction and manifest symptoms such as chest 
tightness, wheeze, cough and shortness of breath.  Your breathing will be monitored and any 
discomfort that may result can and will be reversed by bronchodilator medication.   
 
 118
B.  Study medication 
 
The treatment medication, bronchodilator medication and anti-inflammatory medication are all 
available through prescription.  The doses that will be administered to you in this research 
project do not exceed recommended daily dosages and the possible side effects from these 
medications are not expected.  Some of the more common side effects that have been reported 
with the use of these medications are listed below.   
 
Singulair® - headache (~ 18%), cough, dizziness, fatigue, rash, fever (~all < 5%) 
Desloratadine® - headache (~6%), dry mouth (~3%), fatigue (~3%) 
Ventolin HFA® - throat irritation (10%), cough (5%), viral respiratory infection (7%) 
Flovent HFA® - throat irritation (4%), hoarseness (6%), oral candidiasis (4%) 
 
There is also the potential for unforeseen or unknown risks. 
 
The medication or treatment used in this study may pose a risk to developing fetuses or to babies 
who are being breastfed.  If you are a sexually active woman and are of childbearing potential 
(sexually mature woman who has not undergone a hysterectomy or who has not been post-
menopausal for 24 consecutive months), you must do one of the following while participating in 
this study:  use a medically approved effective method of birth control or abstain from sexual 
intercourse that could result in pregnancy.  If you plan to become pregnant during the course of 
this project you should not participate.  If you are currently breastfeeding, you are not eligible to 
participate in this study. 
 
CONFIDENTIALITY 
 
While absolute confidentiality cannot be guaranteed, every effort will be made to ensure that the 
information you provide for this study is kept entirely confidential.  Your name will not be 
attached to any information, nor mentioned in any study report, nor be made available to anyone 
except the research team.  It is the intention of the research team to publish results of this 
 119
research in scientific journals and to present the findings at related conferences and workshops, 
but your identity will not be revealed. 
 
RESEARCH-RELATED INJURY 
 
There will be no costs to you for participation in this study.  You will not be charged for any 
research procedures.  In the event that you become ill or injured as a result of participating in this 
study, necessary medical treatment will be made available at no additional cost to you.  By 
signing this document you do not waive any of your legal rights. 
 
BENEFITS OF STUDY PARTICIPATION 
 
No one knows whether or not you will benefit from participation in this research study.  There 
may or may not be direct benefits to you if you decide to participate.  We hope that the 
information learned from this study can be used in the future to benefit other people with a 
similar disease. 
 
NEW FINDINGS 
 
If new information about either of the study medications becomes available that may influence 
your willingness to participate in this research project, this information will be provided to you 
by the study personnel. 
 
VOLUNTARY WITHDRAWAL 
 
Your participation in this research is entirely voluntary.  You may withdraw from this study at 
any time.  If you decide to participate and then withdraw before completing all study procedures 
there will be no penalty or loss of benefits to which you are entitled.  Your future medical care 
will not be affected.  If you are a student, your academic status will not be affected.   
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WITHDRAWAL INITIATED BY INVESTIGATOR 
 
The study investigator may decide to discontinue the study at any time, or withdraw you from 
the study at any time if it is felt to be in your best interest. 
STORAGE OF DATA 
 
The data will be stored in the lab where it is collected for a period of 5 years or more as per 
University regulations. 
 
WHO TO CONTACT FOR QUESTIONS ABOUT THE STUDY 
 
If you have any questions about this study, the procedures or treatment involved, or if you would 
like additional information, before or during the study, you may contact study personnel at 966-
8290 or the investigator, Dr. Cockcroft, at 966-8346.  Study personnel can be reached 24 hours at 
229-8709. 
 
WHO TO CONTACT ABOUT YOUR RIGHTS AS A RESEARCH SUBJECT 
 
If you have any questions, concerns or complaints about your rights as a research subject and/or 
your experiences while participating in this study, you should contact the Chair of the 
Biomedical Research Ethics Board, c/o the Office of Research Services, University of 
Saskatchewan at (306) 966-4053. 
 
HONORARIA AND REIMBURSEMENT 
 
You will receive an honorarium ($325.00) for participating in this research project that will 
cover any costs you incur (e.g., parking) as well as compensate you for the time and 
inconvenience of being a research subject.  In the event that you begin the study and 
subsequently withdraw before completing the study, your honorarium will be adjusted 
accordingly. 
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CONSENT 
 
I have read the information sheet regarding this research project. 
I have had sufficient time to consider the information provided. 
I have had the opportunity to ask questions about this project and to receive satisfactory answers 
to my questions. 
I understand that the information will be kept confidential and that the results will only be used 
for scientific purposes. 
I understand that my participation in this study is voluntary and that I am completely free to 
refuse to participate or to withdraw from this study at any time without changing in any way the 
quality of care that I receive. 
I understand that I am not waiving any of my legal rights as a result of signing this consent form. 
I have read the information presented to me and I freely consent to participate in this study. 
I have been told that I will receive a dated and signed copy of this form. 
 
 
 
____________________________       __________________________       ___________ 
Participant signature       Print       Date 
 
 
 
____________________________       __________________________       ___________ 
Signature of person administering     Print       Date 
Consent 
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9.2.3 Certificate of Approval 
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9.3 Appendix C: Study flowchart for the Early Asthmatic Response Study 
   
PHASES SCREENING TREATMENT 
VISIT 1 2 3 4 5 6 7 
DAY -10 -9 -8 0 8 16 24 
Consent Form        
Demographics        
Inclusion/Exclusion        
Concomitant Meds        
Spirometry        
SPT        
MCT        
ACT   (diluent) 
 
(control)     
STE        
Study Meds    
26 and 
2 hours 
pre 
ACT 
 
 
26 and 
2 hours 
pre 
ACT 
 
 
26 and 
2 hours 
pre 
ACT 
 
 
26 and 
2 hours 
pre 
ACT 
 
 
Safety Meds        
 
SPT = skin prick test 
MCT = methacholine challenge test 
ACT = allergen challenge test 
STE = skin test endpoint 
Safety meds = 125 – 250 mcg fluticasone propionate; 100-200mcg salbutamol 
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9.4 Appendix D:  ERJ Abstract of the Late Asthmatic Response Study 
 
Eur Respir J. 2009 Jun;33(6):1302-8. Epub 2009 Jan 22. 
 
Single-dose desloratadine and montelukast and allergen-induced late airway responses. 
 
Davis BE, Illamperuma C, Gauvreau GM, Watson RM, O'Byrne PM, Deschesnes F, Boulet 
LP, Cockcroft DW. 
 
Dept of Pharmacology, Division of Respiratory Medicine, College of Medicine, 
University of Saskatchewan, Saskatoon, SK, Canada. beth.davis@usask.ca 
 
Comment in: 
Expert Opin Pharmacother. 2009 Oct;10(15):2577-9. 
 
Montelukast and desloratadine synergistically inhibit the allergen-induced early asthmatic 
response. Montelukast also suppresses the allergen-induced late asthmatic response, but there are 
no reports on the effect of desloratadine or the combination on the allergen-induced late 
asthmatic response. Atopic asthmatics (n = 10) completed a multicentric randomised double-
blind crossover study comparing single-dose placebo, 5 mg desloratadine, 10 mg montelukast 
and the combination administered 2 h prior to allergen inhalation challenge. Methacholine 
challenges were performed 24 h before and after allergen challenge. Exhaled nitric oxide 
measurements and sputum inflammatory cell counts were also carried out. All active treatments 
significantly decreased the late asthmatic response area under the curve. Combination therapy 
provided the greatest inhibition compared to desloratadine and montelukast. Montelukast was 
nonsignificantly better than desloratadine but not as effective as the combination. There was a 
trend towards a decrease in airway responsiveness following montelukast and combination. 
Montelukast, but not desloratadine or the combination, decreased exhaled NO levels 24 h after 
allergen. The allergen-induced increase in sputum eosinophil numbers was significantly 
suppressed at 7 h with desloratadine and combination therapy, and at 24 h with montelukast and 
combination therapy. Single-dose co-administration of desloratadine and montelukast 2 h prior to 
allergen inhalation clinically abolished the late asthmatic response and eosinophil recruitment. 
 
PMID: 19164343 [PubMed - indexed for MEDLINE] 
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9.5 APPENDIX  E: Ethics Documentation for the Late Asthmatic Response Study 
 
9.5.1 Researcher’s Summary 
 
 
 
 
 
       http://www.usask.ca/research/ethical.shtml 
  
       REB File Number: ________ 
 
 
PROJECT TITLE: Changes in airway responses to inhaled allergen following pharmacological 
inhibition of histamine and CysLT1 blockade in mild atopic asthma 
 
PRINCIPAL INVESTIGATOR:  Dr. D.W. Cockcroft   
 
DEPARTMENT: Medicine, Division of Respiratory, Critical Care and Sleep Medicine  
 
SUB-INVESTIGATOR(S):   
 
DEPARTMENT:  
   
RESEARCH WILL BE CONDUCTED AT: Room 346 Ellis Hall 
________________________________________________________________________ 
 
1. Hypothesis (State briefly the nature and purpose of the research proposal, and the 
proposition the research is seeking to uphold. What potentially useful knowledge or clarification 
about therapeutic options will be advanced to justify the participation of human subjects in this 
research project?) 
 
 Leukotriene receptor antagonism in combination with histamine receptor antagonism will 
provide greater protection against airway responses to inhaled allergen than either drug 
administered alone. 
 
Biomedical Research Ethics Board (Bio-REB) 
RESEARCHER’S SUMMARY FORM 
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2. Academic Validity (Provide evidence that the scientific reasoning and design of the 
project are sufficiently sound to meet the objectives of this project. Provide your own comments 
and if possible those resulting from peer review.  Indicate if any other committee or agency has 
assessed the project’s scientific validity):   
 
Airway responses to inhaled allergen in atopic asthmatics include the early asthmatic response 
(EAR), the late asthmatic response (LAR) and increased airway responsiveness (AHR) to direct 
acting stimuli such as methacholine.  The LAR occurs in about 50% of individuals with atopic 
asthma and is influenced by the magnitude of the EAR.  IgE mediated mast cell degranulation is 
well documented as the mechanism triggering the EAR.  Mediators released during mast cell 
degranulation include the leukotrienes and histamine.  Recent evidence has shown superior 
efficacy against the early asthmatic response following combination therapy with montelukast 
and desloratadine. (BMC#03-1305; Davis BE, Todd DC, Cockcroft DW, J Allergy Clin 
Immunol. 2005 Oct;116(4):768-72).  The mechanism surrounding this apparent synergism is 
unknown.  Investigations into the effect of this particular combination of mast cell mediator 
inhibition on the late asthmatic response, including changes in induced sputum content, exhaled 
nitric oxide, leukocyte trafficking, and the subsequent airway response to methacholine are 
needed to extend the data surrounding the mechanism of action and potential therapeutic benefit. 
 
If applicable, please indicate whether TPD approval has been obtained: 
 
 Yes _____  No _____ Pending _____  N/A __x___ 
 
3. Funding (indicate the source of funds supporting the research.  If externally funded, state 
whether the grant or contract is still in application, or has already been awarded): 
 
Internally funded. 
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4. Disclosure of Potential Conflicts of Interest (indicate any motivation or incentives for 
conducting this study that arise external to the objectives of the study, e.g.,, will the investigator 
or institution be paid to conduct this research project? Note:  The consent form should also 
include an introductory disclosure of potential conflict of interest statement, where applicable, 
indicating that this is a medical research study for which the study doctor, the institution, or both 
are being paid): 
 
 N/A 
 
5. Subjects  
 
a) Target Population (e.g.,, age, gender, medical condition, target enrollment, significant 
inclusion/exclusion criteria): 
 
Nine-twelve well controlled atopic asthmatics 18 years of age or older, male or female. 
 
Inclusion: 
Baseline FEV1 ≥ 65% predicted 
Methacholine PC20 ≤ 16mg/ml 
EAR ≥ 20% 
LAR ≥ 15% 
 
Exclusion: 
Respiratory infection within 4 weeks of screening visit 
Diagnosis of another respiratory disease other than asthma 
Pregnant or lactating 
 
b) Proposed Strategies for Recruitment (e.g.,, use of advertisements, brochures, physician patient 
records):  
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Recruitment will likely be completed with individuals who have previously participated in 
research and have agreed to being contacted for future projects.   
Poster advertisement around campus as well as the university hospital may be undertaken.  An ad 
may also be placed in the university newspaper.  Any advertising will be submitted to the REB 
for approval prior to posting. 
 
6. Procedures (clearly identify treatment allocation design, and describe the medical and 
other procedures to be followed in obtaining research data, including questionnaires): 
 
The study design will be a randomized, four way crossover, placebo controlled study.  
Treatments will be administered (oral) 2 hours prior to allergen challenges.  Subjects will be 
required to undergo skin prick tests, blood tests, methacholine challenges and allergen 
challenges, as well as perform spirometry measurements, exhaled nitric oxide measurements and 
sputum induction. 
 
See attached appendices for specific details. 
 
7. Time Period (indicate the dates when the research project is expected to begin and to be 
completed.  A final status report must be filed with the Ethics Office once data collection from 
the last subject is complete. The Ethics Office should be notified once the study site is closed.): 
 
November 2006 - November 2007 
 
8.    Data Storage (In accordance with recommended guidelines provide a statement outlining the 
procedures you will use to store securely the research data.  State how long and where the data 
will be stored and identify the person who will be assuming responsibility for data storage): 
 
Dr. Cockcroft will store the data in Room 346 Ellis Hall for at least five years. 
 129
9. Consent Form (include a copy of the consent form and/or any study information that will 
be used.  If not using a consent form give reasons why).   
 
Attached 
 
 
10. Signatures 
   
 ______________________________ 8346     
 Principal Investigator    Phone 
 
 8294      cockcroft@sask.usask.ca  
 Fax      e-mail 
 
 _______________________________________ 
 Department Head, Dean, Director, or Administrative Head   
 
10. Contact Person and Mailing Address for Correspondence: 
 
 Beth Davis c/o Dr. Cockcroft, Division of Respiratory Medicine, 5th Floor Ellis Hall, 
 103 Hospital Drive, Saskatoon, SK S7N 0W8.  Phone: 966-8290. E-mail: 
 beth.davis@usask.ca 
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9.5.2 Information Sheet and Consent Form 
 
 
INFORMATION SHEET AND CONSENT FORM 
 
Title: Changes in airway responses to inhaled allergen following pharmacological 
inhibition of histamine and CysLT1 blockade in mild atopic asthma. 
Investigator:  Dr. D.W. Cockcroft 
Department of Medicine, Division of Respiratory Medicine 
University of Saskatchewan 
5th Floor Ellis Hall, 103 Hospital Drive 
Saskatoon, Saskatchewan S7N 0W8 
306-966-8346 
 
 
INTRODUCTION 
 
You are being invited to participate in a research project because you have allergies that trigger 
your asthma.  Currently available asthma (montelukast) and allergy (desloratadine) medications 
and their combined effect on people who have allergies that trigger their asthma will be 
investigated.  We expect to enroll 9-12 people in this study. The University of Saskatchewan 
and/or Dr. Cockcroft are not being paid to conduct this study. 
 
VOLUNTARY PARTICIPATION 
 
Your participation is entirely voluntary and it is up to you to decide whether or not you want to 
take part in this project.  Before you decide, it is important for you to understand what the 
research involves.  This document will tell you about the study, why the research is being done, 
what will happen to you during the study and the possible benefits, risks and discomforts. 
If you wish to participate, you will be asked to sign this form.  If you decide to take part in this 
study you may still withdraw at any time and without giving any reason. 
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If you decide not to participate, you do not have to provide any reason for your decision and you 
will not lose any medical care to which you are entitled or are presently receiving. 
Please take time to read the following information carefully and to discuss it with your family, 
friends, and/or doctor before you decide. 
 
PURPOSE 
 
Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current 
uses.  Part of what happens when your allergies trigger your asthma should be prevented by 
either of these drugs.  This project is being conducted to determine if these drugs are effective, 
either alone or in combination, on controlling asthma that is triggered by allergies. 
 
PROCEDURES 
 
The duration of the study is approximately 6 weeks and can be divided into two phases, a 
screening phase (testing to determine if you qualify) and a treatment phase (collection of the data 
to be analyzed).  You will be required to attend the lab on at least 15 occasions (3 consecutive 
day visits on 5 different occasions) during the course of the study.  The duration of each visit will 
vary.  Screening procedures will occur over three days.  The first and third days will require 
about two hours of your time.  The second day will require about nine hours of your time.  The 
treatment phase visits will require these same time commitments.  If you decide to participate in 
this research project, you will be required to complete the following testing: 
 
A.  Breathing Tests 
  
Breathing tests will be conducted at all visits.  You will be required to blow into a piece of 
equipment that you hold in your hand.  The equipment has a mouthpiece attached to it which you 
will place in your mouth.  You will inhale and exhale through the mouthpiece with nose clips on.  
The air that goes through the machine is measured by a software program that displays the 
results on a computer screen. 
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B.  Skin Prick Tests 
 
The skin prick test will be conducted once.  This will involve small droplets of common 
allergens (animals, pollens, etc.) being placed on your forearm.  A small scratch within the 
droplet will be performed which will determine if you have an allergy to a particular allergen.  If 
so, a small bump similar to a mosquito bite will appear and will likely be red and itchy. 
 
C.  Skin test endpoint 
 
The skin test endpoint is identical to the skin prick test except that one allergen (chosen from the 
results of the skin prick test) of various concentrations is placed on the forearm, scratched and 
monitored for response.  This test will be done once. 
 
D.  Exhaled nitric oxide 
 
We will measure the amount of nitric oxide that you exhale through another piece of equipment 
that is also attached to a mouthpiece.  You will need to place the mouthpiece in your mouth, 
inhale until your lungs are full and exhale through the mouthpiece.  You do not need to wear 
noseclips for this test.  This measurement is an indication of airway inflammation. 
 
E.  Methacholine Inhalation Test 
 
The methacholine inhalation test will be conducted a minimum of 10 times.  This will involve 
breathing maneuvers as described above.  In addition, you will be required to inhale a substance 
called methacholine which may cause your airway to constrict.  You will be inhaling increasing 
concentrations of methacholine by placing a mask over your nose and mouth. The mask is 
attached to an aerosol generating piece of equipment which functions to provide an inhalable 
solution of the substance.  You will inhale the substance by breathing normally for two minutes.  
Any constriction that may result will be monitored by the breathing maneuvers.  When and if a 
certain value is reached (20% decrease), the test will be stopped. 
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F.  Sputum induction 
 
After the methacholine challenge test, you will be given two puffs of Ventolin® .  You will then 
be required to inhale hypertonic (salty) saline solutions which should help you produce 
secretions (sputum) from your airways.  You do not need to wear noseclips.  You will inhale the 
solutions through a mouthpiece.  You will spit the sputum into a cup.  The sputum is then 
processed and analyzed for changes that are occurring with the cells in your airway.  This test 
will be done at every visit. 
 
G.  Allergen Challenge Test 
 
The allergen challenge test will be performed on five occasions.  Each allergen challenge will be 
separated by at least 7 days.  Again, breathing maneuvers will be performed as described above 
and will be used to monitor any constriction that occurs.  You will be required to inhale 
increasing concentrations of one of the allergens identified in the skin prick test and used for the 
skin test endpoint.  The inhalation is done through a mouthpiece with a noseclip on for two 
minutes of normal breathing.  When the constriction in your airways reaches a certain value 
(15%) the test will be stopped and your breathing will be monitored at various time points for the 
next 7 hours.  Again, you may stop the test at any time for any reason. 
 
H.  Blood tests 
 
Two tubes of blood (approximately 10mL) will be drawn from a vein in your arm at each visit. 
 
I.  Administration of the drugs, montelukast and desloratadine 
 
This is a placebo controlled study.  Placebo controlled means there are tablets that look like the 
active drug but do not contain any active drug.  To accurately assess the effect of the treatments 
on blocking the response to allergen we need to have a placebo arm which serves as the baseline 
for calculating any protection the three active treatments might have.  There are four separate 
treatments (montelukast alone, desloratadine alone, montelukast + desloratadine and placebo).  
 134
You will be required to complete all four, but in no particular (i.e random) order.  Neither you 
nor the study personnel will know what treatment you are taking.  This information can however 
be obtained if necessary and will be available at the end of the study. 
 
Both montelukast and desloratadine are currently available by prescription under the trade names 
Singulair® and Aerius® (CAN)/Clarinex® (US) respectively.  The recommended dosage is 
10mg a day for Singulair® and 5mg a day for Aerius®.  This will be the dose you will be 
required to take two hours before each allergen challenge. 
 
The study table on page 7 provides an overview of what tests you will be doing on what days and 
approximately how long your visit will be.   
 
ALLOWED/DISALLOWED MEDICATIONS  
 
For safety reasons, the use of any other drugs (or herbal supplements) should be discussed with 
study personnel, prior to their use.  The table below provides some guidance on what 
medications can and cannot be used.  
 
ALLOWED DISALLOWED 
Ventolin Withhold for 6 hours before a visit Singulair Flovent 
Atrovent Withhold for 8 hours before a visit Pulmicort Oxeze 
Airomir Withhold for 6 hours before a visit Salmeterol Symbicort 
Acetaminophen No time restriction Advair Antihistamines 
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RISKS AND DISCOMFORTS 
 
A.  Methacholine and allergen inhalation tests 
 
The inhalation challenges may cause bronchoconstriction and manifest symptoms such as chest 
tightness, wheeze, cough and shortness of breath.  Your breathing will be monitored and any 
discomfort that may result can be reversed by bronchodilator medication. 
 
There is the potential for a severe allergic reaction (anaphylaxis) to occur during an allergen.  
Safety measures are in place to minimize the likelihood of this occurring as well as to treat such 
an event should it occur. 
 
B.  Study medication 
 
The treatment medication and bronchodilator medication (Ventolin®) are available through 
prescription.  The doses that will be administered to you in this research project do not exceed 
recommended daily dosages and the possible side effects from these medications are not 
expected.  Some of the more common side effects that have been reported with the use of these 
medications are listed below.   
 
Singulair® - headache (~ 18%), cough, dizziness, fatigue, rash, fever (~all < 5%) 
Desloratadine® - headache (~6%), dry mouth (~3%), fatigue (~3%) 
Ventolin HFA® - throat irritation (10%), cough (5%), viral respiratory infection (7%) 
 
There is also the potential for unforeseen or unknown risks. 
 
C.  Reproductive risks 
 
The medication or treatment used in this study may pose a risk to the developing fetus or to 
babies who are breastfeeding.  If you are a sexually active woman and are of childbearing 
potential (sexually mature woman who has not undergone a hysterectomy or who has not been 
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post-menopausal for 24 consecutive months), you must do one of the following while 
participating in this study:  use a medically approved effective method of birth control (e.g., oral 
or implanted contraceptives, intrauterine device, diaphragm with spermicide or cervical cap) or 
abstain from sexual intercourse that could result in pregnancy.  If you plan to become pregnant 
during the course of this project you should not participate.  If you are currently breastfeeding, 
you are not eligible to participate in this study. 
 
A urine pregnancy test will be conducted during screening for all females you are of child 
bearing potential. 
 
D.  Sputum induction 
 
The inhalation of hypertonic saline may cause your airways to constrict.  This is prevented by 
administered the 2 puffs of Ventolin® after the methacholine challenge and before the sputum 
induction process.  Your breathing will be monitored and you can stop the test at any time for 
any reason. 
 
E.  Blood tests 
 
The “needle poke” that is required to draw your blood may cause some discomfort.  Bruising 
around the area the needle entered may also occur.  The occurrence of infection following the 
drawing of blood is rare but has occurred.  
 
CONFIDENTIALITY 
 
While absolute confidentiality cannot be guaranteed, every effort will be made to ensure that the 
information you provide for this study is kept entirely confidential.  Your name will not be 
attached to any information, nor mentioned in any study report, nor be made available to anyone 
except the research team.  It is the intention of the research team to publish results of this 
research in scientific journals and to present the findings at related conferences and workshops, 
but your identity will not be revealed. 
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RESEARCH-RELATED INJURY 
 
There will be no costs to you for participation in this study.  You will not be charged for any 
research procedures.  In the event that you become ill or injured as a result of participating in this 
study, necessary medical treatment will be made available at no additional cost to you.  By 
signing this document you do not waive any of your legal rights. 
 
BENEFITS OF STUDY PARTICIPATION 
 
There is no medical or other benefit to you as an individual as a result of your being in this study. 
We hope that the information learned from this study can be used in the future to benefit other 
people with a similar disease, however, no benefit is guaranteed. 
 
NEW FINDINGS 
 
If new information about either of the study medications becomes available that may influence 
your willingness to participate in this research project, this information will be provided to you 
by the study personnel. 
 
VOLUNTARY WITHDRAWAL 
 
Your participation in this research is entirely voluntary.  You may withdraw from this study at 
any time.  If you decide to participate and then withdraw before completing all study procedures 
there will be no penalty or loss of benefits to which you are entitled.  Your future medical care 
will not be affected.  If you are a student, your academic status will not be affected.   
 
WITHDRAWAL INITIATED BY INVESTIGATOR 
 
The study investigator may decide to discontinue the study at any time, or withdraw you from 
the study at any time if it is felt to be in your best interest. 
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STORAGE OF DATA 
 
The data will be stored in the lab where it is collected for a period of 5 years or more as per 
University regulations. 
 
WHO TO CONTACT FOR QUESTIONS ABOUT THE STUDY 
 
If you have any questions about this study, the procedures or treatment involved, or if you would 
like additional information, before or during the study, you may contact study personnel at 966-
8290 or the investigator, Dr. Cockcroft, at 966-8346.  Study personnel can be reached 24 hours at 
229-8709. 
 
WHO TO CONTACT ABOUT YOUR RIGHTS AS A RESEARCH SUBJECT 
 
If you have any questions, concerns or complaints about your rights as a research subject and/or 
your experiences while participating in this study, you should contact the Chair of the 
Biomedical Research Ethics Board, c/o Ethics Office, University of Saskatchewan at (306) 966-
4053. 
 
HONORARIA AND REIMBURSEMENT 
 
You will receive an honorarium for participating in this research project that will cover any costs 
you incur (e.g., parking and meals) as well as compensate you for the time and inconvenience of 
being a research subject.  In the event that you begin the study and subsequently withdraw before 
completing the study, your honorarium will be adjusted accordingly. 
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CONSENT 
 
I have read the information sheet regarding this research project. 
I have had sufficient time to consider the information provided. 
I have had the opportunity to ask questions about this project and to receive satisfactory answers 
to my questions. 
I understand that the information will be kept confidential and that the results will only be used 
for scientific purposes. 
I understand that my participation in this study is voluntary and that I am completely free to 
refuse to participate or to withdraw from this study at any time without changing in any way the 
quality of care that I receive. 
I understand that I am not waiving any of my legal rights as a result of signing this consent form. 
I have read the information presented to me and I freely consent to participate in this study. 
I have been told that I will receive a dated and signed copy of this form. 
 
 
 
____________________________       __________________________       ___________ 
Participant signature       Print       Date 
 
 
 
____________________________       __________________________       ___________ 
Signature of person administering     Print       Date 
Consent 
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9.5.3 Certificate of Approval 
 
 9.6 APPENDIX F:  Study Flowchart for the Late Asthmatic Response Study 
 
PHASE SCREENING TREATMENT 1 TREATMENT 2 TREATMENT 3 TREATMENT 4 
VISIT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
DAY 1 2 3 10 11 12 19 20 21 28 29 30 37 38 39 
Consent Form ●               
Demographics ●               
Inclusion/Exclusion ●               
Con Meds ●               
SPT ●               
STE ●               
FeNO ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
MCT ●  ● ●  ● ●  ● ●  ● ●  ● 
Sputum ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Urine Pregnancy 
Test ●               
Blood collection ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
ACT  ●   ●   ●   ●   ●  
Study Drug Admin     ●   ●   ●   ●  
Adverse Events ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Time Required 
(hours) 1.5 9 1.5 1.5 9 1.5 1.5 9 1.5 1.5 9 1.5 1.5 9 1.5 
SPT = skin prick test 
STE = skin test endpoint 
FeNO = fraction of exhaled nitric oxide 
MCT = methacholine challenge test 
ACT = allergen challenge test 
Note that there is a “washout period” between the screening visits and Treatment 1 and 
between Treatments 1 and 2, Treatments 2 and 3 and Treatments 3 and 4.  This is a 
minimum of 7 days. No visits are required during this time. 
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